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ABSTRACT 
 
EFFECTIVENESS AND SAFETY OF FOUR-FACTOR PROTHROMBIN COMPLEX AND FRESH FROZEN 
PLASMA IN CARDIAC SURGERY 
 
Objectives: The purpose of this study was to (i) describe the utilization pattern of four-factor 
prothrombin complex concentrate (4PCC) and fresh frozen plasma (FFP) used intraoperatively in 
coronary artery bypass graft (CABG) and valve surgeries requiring cardiopulmonary bypass (CPB) (ii) 
evaluate the factors associated with use of 4PCC or FFP intraoperatively in CABG and valve surgeries 
requiring CPB (iii) evaluate the effectiveness of 4PCC used intraoperatively in CABG and valve surgeries 
requiring CPB (iv), and assess the safety of 4PCC used intraoperatively in CABG and valve surgeries 
requiring CPB. 
Methods: This retrospective, cohort study identified all CABG, valve repair, and valve 
replacement surgeries from March 2014 to April 2016 at Houston Methodist Hospital (HMH), Houston, 
Texas. Patients included in the study were 18 years of age or older and receiving CABG and/or valve 
surgery requiring CPB. Patients who received other cardiac procedures during the CABG or valve 
procedure were excluded as well as patients receiving both FFP and 4PCC intraoperatively. The data 
sources for this study included institutional electronic health records (EHR), claims from Vizient, and 
clinical measures, comorbidities, and outcomes from the Society of Thoracic Surgeons (STS).  The 4PCC 
and FFP exposures were identified from charge claims extracted from the Vizient database and validated 
from the EHR. Descriptive statistics were performed to assess the utilization pattern of 4PCC and FFP 
used intraoperatively in CABG and valve procedures, and three multivariable logistic regression models 
were created to determine the predictive factors of using 4PCC or FFP intraoperatively. The independent 
variables in the multivariable models were selected based on the Andersen Behavior Model and 
hypothesized that predisposing, enabling, and need factors that influence the use of these agents. The 
dependent variables in these logit models were the exposure of 4PCC, FFP, or 4PCC versus FFP. The 
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primary endpoint evaluating the effectiveness of 4PCC versus FFP was the proportion of patients who 
received a red blood cell (RBC) transfusion intraoperatively or within 24 hours postoperatively. 
Multivariable logistic regression using backward elimination was performed to determine the 
effectiveness of 4PCC versus FFP administered intraoperatively with the dependent variable as RBC 
utilization. A sensitivity analyses on the primary endpoint was performed by creating a propensity score 
for the exposures of 4PCC versus FFP, then using the score as a regressor in a logistic regression model 
to validate the study findings.  The safety of 4PCC compared to FFP was evaluated by performing 
bivariate statistical analysis with a focus on thromboembolic events.  
Results: During the study timeframe, a total of 924 patients were identified for the purpose of 
the study of the 1,946 patients who underwent CABG and/or valve surgery;  690 patients (70.2%) did 
not receive FFP or 4PCC intraoperatively (control), 166 patients (16.9%) received 4PCC only, 68 patients 
(6.9%) received FFP only, and 58 (5.9%) received both 4PCC and FFP intraoperatively. . More patients in 
the control and FFP groups underwent CABG alone (Control: 329 (56.8%); FFP: 33 (48.5%), and less 
patients in the control and FFP groups had valve procedures alone compared to the 4PCC group 
(Control: 247 (35.8%); FFP: 27 (39.7%). The control group also had significantly less repeat open-chests 
compared to the FFP and 4PCC groups (Control: 68 (9.9%); FFP: 14 (20.6%), 4PCC: 40 (24.1)). In addition, 
the control group had significantly shorter surgeries, CPB time, aortic cross-clamp time (ACT), and 
required less cell saver units compared to the FFP and 4PCC groups, while the FFP and 4PCC groups did 
not differ on any of the aforementioned measures.  
Factors positively associated receiving 4PCC compared to the control included the predisposing 
factor age (years) and need factors like international normalized ratio (INR), cell saver use (units), CPB 
time (min), and desmopressin use, and need factors negatively associated receiving 4PCC compared to 
the control included body mass index (BMI) (kg/m2), hematocrit (HCT) (%), platelets greater than 150 
109/L, cardiac arrhythmia, dyslipidemia, and ε-aminocaproic acid (EACA) intraoperative use. Need 
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factors associated with an increase in the odds of receiving FFP compared to the control were patients 
undergoing an emergent procedure, history of cerebrovascular disease (CVD), and cell saver use (units). 
Lastly, patients were more likely to receive 4PCC compared to FFP with each unit increase in cell saver 
use, if desmopressin was administered intraoperatively, and if the patient had HTN. Factors decreasing 
the likelihood of receiving 4PCC compared to FFP were patients that had dyslipidemia, liver dysfunction, 
and HCT (%).  
In the unadjusted bivariate comparison of patients requiring RBC transfusion, patients receiving 
4PCC compared to FFP required less RBC transfusions intraoperatively and/or within 24 hours 
postoperatively (OR=0.43; 4PCC: 100/166 (60%) vs. FFP: 53/68 (78%); p-value=0.01). For the primary 
endpoint, the multivariable logistic regression model comparing patients receiving FFP intraoperatively 
to 4PCC found patients receiving 4PCC had a significant reduction in the odds of receiving an RBC 
transfusion intraoperatively and/or within 24 hours postoperatively (OR: 0.28; 95% CI: 0.13-0.62).  The 
sensitivity analyses revealed patients receiving 4PCC compared to FFP also significantly reduced the 
odds of receiving an RBC transfusion intraoperatively and/or within 24 hours postoperatively (OR: 0.41; 
95% CI: 0.19-0.89).  
More patients who received 4PCC had venous thromboembolism (8.4%) compared to the 
control (2.9%; p-value=0.001) but not compared to the FFP group (2.9%; p-value=0.162). No differences 
were found in the number of patients who had a stroke/ transient ischemic attack in the control (1.9%), 
FFP (0%), and 4PCC (3.0%) groups. 
Conclusions: This study found approximately 1 out of 5 patients received 4PCC intraoperatively 
with or without FFP, and approximately 1 out of 14 patients received FFP alone intraoperatively.    The 
study findings suggest that intraoperative use of FFP and 4PCC is mainly occurring in patients with 
excessive bleeding evidenced by the significant relationship of need factors including cell saver use with 
their administration. In patients undergoing isolated CABG and/or valve surgery requiring CPB with 
Colavecchia 9 
 
indications of excessive bleeding, intraoperative administration of 4PCC compared to FFP can reduce a 
patient’s likelihood of requiring an RBC transfusion intraoperatively and up to 24 hours postoperatively. 
4PCC should be used cautiously in hypercoaguable patients or patients with a history of thrombosis and 
only prescribed in the context of excessive bleeding.  
 
Key words: four-factor prothrombin complex concentrate, fresh frozen plasma, factor concentrate, 
fibrinogen concentrate, transfusion, coronary artery bypass, valve repair, valve replacement, surgery 
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ACRONYMS 
 
 
  
Acronym Description 
4PCC four-factor prothrombin complex concentrate 
ACT aortic cross clap time 
AKI  acute kidney injury 
aPTT  activated partial thromplastin time 
BMI  body mass index 
CABG coronary artery bypass graft 
CLD chronic lung disease 
CPB cardiopulmonary bypass 
Cryo  cryoprecipitate (15 mL per unit) 
CVP  central venous pressure 
DBP  diastolic blood pressure 
DM diabetes 
EACA  epsilon-aminocaproic acid 
FC Factor concentrate 
FFP  fresh frozen plasma (250 mL per unit) 
FibC  fibrinogen concentrate 
HD  hemodialysis 
HF heart failure 
HTN hypertension 
ICU  intensive care unit 
INR  international normalized ratio 
LOS  length of stay 
LVEF left ventricular ejection fraction 
MELD  Model For End-Stage Liver Disease 
MI myocardial infarction 
OR operating room 
PAD peripheral artery disease 
PE pulmonary embolism 
Plt  platelet (200 mL per dose) 
PNA pneumonia 
RBC  red blood cell (300 mL per unit) 
RCT randomized controlled trial 
RRT renal replacement therapy 
SBP  systolic blood pressure 
SCr serum creatinine 
SD  standard deviation 
TIA transient ischemic attack 
VTE venous thromboembolism 
Colavecchia 11 
 
Table of Contents 
 
STUDY RATIONALE ................................................................................................................................. 13 
OBJECTIVES ............................................................................................................................................. 14 
MAIN FINDINGS ...................................................................................................................................... 15 
CONCLUSIONS ........................................................................................................................................ 16 
IMPLICATIONS OF RESEARCH ................................................................................................................. 17 
REFERENCES ............................................................................................................................................ 18 
CHAPTER II: Risk factors predicting the use of 4PCC and FFP in cardiac surgery ..................................... 22 
INTRODUCTION ...................................................................................................................................... 22 
METHODS ............................................................................................................................................... 24 
DESIGN AND SETTING ......................................................................................................................... 24 
DATA SOURCES AND COLLECTION PROCEDURE ................................................................................ 24 
STUDY POPULATION........................................................................................................................... 25 
CONCEPTUAL FRAMEWORK: ANDERSEN BEHAVIORAL MODEL ....................................................... 26 
SURGICAL PROCEDURE AND OPERATIVE MANAGEMENT ................................................................ 27 
STUDY VARIABLES AND DEFINITIONS ................................................................................................ 28 
STATISTICAL ANALYSIS ....................................................................................................................... 33 
RESULTS .................................................................................................................................................. 35 
FREQUENCY OF 4PCC AND FFP USE IN CARDIAC SURGERY .............................................................. 35 
PREDICTORS OF 4PCC USE IN CARDIAC SURGERY ............................................................................. 35 
PREDICTORS OF FFP USE IN CARDIAC SURGERY ............................................................................... 36 
PREDICTORS OF 4PCC COMPARED TO FFP USE IN CARDIAC SURGERY ............................................ 36 
DISCUSSION ............................................................................................................................................ 36 
STRENGTHS AND LIMITATIONS .......................................................................................................... 40 
CONCLUSION .......................................................................................................................................... 40 
REFERENCES ............................................................................................................................................ 40 
CHAPTER III: Effective and safety of 4PCC compared to FFP in cardiac surgery ...................................... 45 
INTRODUCTION ...................................................................................................................................... 45 
METHODS ............................................................................................................................................... 46 
DESIGN AND SETTING ......................................................................................................................... 46 
DATA SOURCES AND COLLECTION PROCEDURE ................................................................................ 47 
STUDY POPULATION........................................................................................................................... 48 
Colavecchia 12 
 
SURGICAL PROCEDURE AND OPERATIVE MANAGEMENT ................................................................ 49 
STUDY OUTCOMES AND DEFINITIONS .............................................................................................. 50 
STATISTICAL ANALYSIS ....................................................................................................................... 56 
RESULTS .................................................................................................................................................. 59 
STUDY POPULATION........................................................................................................................... 59 
STUDY GROUP COMPARISONS AND UNADJUSTED PATIENT OUTCOMES ....................................... 59 
MULTIVARIABLE REGRESSION MODEL AND SENSITIVITY ANALYSIS ................................................ 60 
SAFETY OUTCOMES ............................................................................................................................ 61 
DISCUSSION ............................................................................................................................................ 61 
STRENGTHS AND LIMITATIONS .......................................................................................................... 64 
CONCLUSIONS ........................................................................................................................................ 65 
REFERENCES ............................................................................................................................................ 66 
CHAPTER IV: Conclusions ........................................................................................................................... 69 
TABLES ........................................................................................................................................................ 71 
Chapter II Tables ..................................................................................................................................... 71 
Chapter III Tables .................................................................................................................................... 79 
FIGURES ...................................................................................................................................................... 86 
APPENDIX ................................................................................................................................................... 88 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Colavecchia 13 
 
CHAPTER I:  
EXECUTIVE SUMMARY 
STUDY RATIONALE 
In the United States more than 300,000 CABG procedures and over 100,000 valve procedures 
are performed each year.1 Considering the large volume of these cardiac procedures in the US, 
cardiothoracic procedures are estimated to use approximately 25% of blood products globally.2 Major 
bleeding during and post open-heart surgery requiring cardiopulmonary bypass (CPB) occurs frequently 
and may result in increased morbidity and mortality, re-exploration post-surgery, and require 
considerable blood product transfusions. 3-17 Acute blood loss requiring transfusion of blood products 
(i.e. red blood cells (RBCs) or fresh frozen plasma (FFP)) is associated with increased risk of infection, 
transfusion-related lung injury (TRALI), transfusion-associated circulatory overload (TACO), acute renal 
failure, thromboembolic events, transfusion-related immunomodulation (TRIM), and 
allergic/anaphylactic reactions.3-17  
The aforementioned adverse effects associated with blood product transfusions has led 
providers to seek other alternative therapies to FFP and allogeneic blood derivatives to mitigate blood 
transfusion requirements during procedures. Initially approved for the reversal of acute major bleeding 
caused by vitamin K antagonist therapy, four-factor prothrombin complex concentrate (4PCC) contains a 
high concentration of lyophilized clotting factors II, VII, IX, X, and protein C and S and rapidly reverses 
coagulopathy in specific scenarios.18 4PCC offers several benefits when used to minimize bleeding 
compared to FFP that include a faster onset, increased potency, small volume, and ability to administer 
more quickly due to quick reconstitution.18 While 4PCC may offer a useful alternative to decrease 
perioperative bleeding, these products also carry risks including thromboembolic events, infusion-
related reactions, hypotension, acute kidney injury, and cost.18,19 
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Since STS last updated its guidelines on blood conservation strategies for cardiac surgery in 
2011, the society does not provide specific guidance on the use of PCC versus FFP, except for the urgent 
reversal of warfarin prior to the procedure.20 The European Society of Anaesthiologists recommend the 
use of PCC intraoperatively in the presence of an elevated bleeding tendency and prolonged clotting 
time, where the adoption of PCC products in clinical practice has increased.21 With surgery teams having 
access to both FFP and/or PCC, knowing the factors predicting their administration will assist in 
establishing best practices for their use and improve future prescribing. Also, no studies have been 
published comparing the factors predictive of using FFP versus PCC in cardiac surgery. Currently, mixed 
evidence supports the use of 4PCC compared to FFP to mitigate blood loss in cardiac surgery, and 
limited comparative data exists regarding 4PCC and FFP in CABG and valve surgery.22-27  
Overall limited evidence exists regarding the safety and effectiveness of using prothrombin 
complex concentrates to minimize blood product use intra and postoperatively. The proposed study will 
provide a significant contribution to the literature, because it offers a real-world analysis regarding the 
predictive factors for using 4PCC versus FFP as well as the safety and effectiveness of 4PCC compared to 
FFP in CABG and valve procedures. Only one other nonrandomized study has been published assessing a 
3PCC product administered to normocoaguable patients receiving CABG and/or valve procedures in an 
Italian hospital, and no large randomized or nonrandomized studies have been published assessing 4PCC 
in CABG and valve procedures.24 
OBJECTIVES 
The objectives of this study were to: 
1. Describe the utilization of four-factor prothrombin complex concentrate (4PCC) and fresh 
frozen plasma (FFP) used intraoperatively in coronary artery bypass graft (CABG) and valve 
surgeries requiring cardiopulmonary bypass (CPB);  
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2. Evaluate the factors associated with use of 4PCC or FFP intraoperatively in CABG and valve 
surgeries requiring CPB; 
3. Evaluate the effectiveness of 4PCC versus FFP used intraoperatively in CABG and valve surgeries 
requiring CPB; and 
4. Assess the safety of 4PCC used intraoperatively in CABG and valve surgeries requiring CPB. 
MAIN FINDINGS 
This retrospective, cohort study identified all CABG, valve repair, and valve replacement 
surgeries from March 2014 to April 2016 at Houston Methodist Hospital (HMH), Houston, Texas. During 
the study timeframe, a total of 924 patients were identified for the purpose of the study of the 1,946 
patients who underwent CABG and/or valve surgery; 690 patients (70.2%) did not receive FFP or 4PCC 
intraoperatively (control), 166 patients (16.9%) received 4PCC only, 68 patients (6.9%) received FFP only, 
and 58 (5.9%) received both 4PCC and FFP intraoperatively. More patients in the control and FFP groups 
underwent CABG alone (Control: 329 (56.8%); FFP: 33 (48.5%), and less patients in the control and FFP 
groups had valve procedures alone compared to the 4PCC group (Control: 247 (35.8%); FFP: 27 (39.7%). 
The control group also had significantly less repeat open-chests compared to the FFP and 4PCC groups 
(Control: 68 (9.9%); FFP: 14 (20.6%), 4PCC: 40 (24.1)). In addition, the control group had significantly 
shorter surgeries, CPB time, aortic cross-clamp time (ACT), and required less cell saver units compared 
to the FFP and 4PCC groups, while the FFP and 4PCC groups did not differ on any of the aforementioned 
measures.  
Factors positively associated receiving 4PCC compared to the control included predisposing 
factor age (years) and need factors like international normalized ratio (INR), cell saver use (units), CPB 
time (min), and desmopressin use, and need factors negatively associated receiving 4PCC compared to 
the control included body mass index (BMI) (kg/m2), hematocrit (HCT) (%), platelets greater than 150 
109/L, cardiac arrhythmia, dyslipidemia, and ε-aminocaproic acid (EACA) intraoperative use. Need 
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factors associated with an increase in the odds of receiving FFP compared to the control were patients 
undergoing an emergent procedure, history of cerebrovascular disease (CVD), and cell saver use (units). 
Lastly, patients were more likely to receive 4PCC compared to FFP with each unit increase in cell saver 
use, if desmopressin was administered intraoperatively, and if the patient had HTN. Factors decreasing 
the likelihood of receiving 4PCC compared to FFP were patients that had dyslipidemia, liver dysfunction, 
and HCT (%).  
In the unadjusted bivariate comparison of patients requiring RBC transfusion, patients receiving 
4PCC compared to FFP required less RBC transfusions intraoperatively and/or within 24 hours 
postoperatively (OR=0.43; 4PCC: 100/166 (60%) vs. FFP: 53/68 (78%); p-value=0.01). For the primary 
endpoint, the multivariable logistic regression model comparing patients receiving FFP intraoperatively 
to 4PCC found patients receiving 4PCC had a significant reduction in the odds of receiving an RBC 
transfusion intraoperatively and/or within 24 hours postoperatively (OR: 0.28; 95% CI: 0.13-0.62).  The 
sensitivity analyses revealed patients receiving 4PCC compared to FFP also significantly reduced the 
odds of receiving an RBC transfusion intraoperatively and/or within 24 hours postoperatively (OR: 0.41; 
95% CI: 0.19-0.89).  
More patients who received 4PCC had venous thromboembolism (8.4%) compared to the 
control (2.9%; p-value=0.001) but not compared to the FFP group (2.9%; p-value=0.162). No differences 
were found in the number of patients who had a stroke/ transient ischemic attack in the control (1.9%), 
FFP (0%), and 4PCC (3.0%) groups. 
CONCLUSIONS 
This retrospective, single-institution study found an increasing number of patients receiving 
4PCC compared to FFP to mitigate blood loss in cardiac surgery. Based on the Andersen Behavioral 
model, predictive factors of administering 4PCC and FFP vary in cardiac surgery, and these factors offer 
insight into patients’ comorbidities and clinical variables associated with their use. In patients 
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undergoing CABG and/or valve surgery requiring CPB with indications of excessive bleeding, 
intraoperative administration of 4PCC may reduce a patient’s likelihood of requiring an RBC transfusion 
intraoperatively and up to 24 hours postoperatively compared to patients receiving FFP. 4PCC should be 
used cautiously in hypercoagulable patients or patients with a history of thrombosis, because 4PCC may 
increase the risk of thromboembolic events post-cardiac surgery. 
IMPLICATIONS OF RESEARCH 
By identifying pertinent factors predicting the use of FFP and/or 4PCC, subsequent studies may 
be performed that target the clinical utility of 4PCC compared to FFP in patients with specific 
comorbidities such as CVD, liver dysfunction, and HTN. Knowing which patient populations benefit most 
from 4PCC versus FFP will provide more effective, safer, and individualized care for patients during 
cardiac surgery. 
This study found 4PCC to mitigate blood loss in CABG and valve procedures when patients have 
excessive bleeding compared to FFP and may offer a viable blood conservation strategy. With our study 
supporting the results found by Cappabianca and colleagues,24 institutions need to assess the clinical 
utility of 4PCC as an alternative blood conservation strategy to FFP in cardiac surgery. Finally, the cost-
effectiveness of 4PCC versus FFP for the treatment of excessive bleeding in cardiac procedures needs to 
be determined to inform payers and institutions about the financial impact of adopting this treatment 
strategy. 
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CHAPTER II: 
RISK FACTORS PREDICTING THE USE OF 4PCC AND FFP IN CARDIAC 
SURGERY 
 
INTRODUCTION 
According to a survey performed in 2007, cardiothoracic procedures use an estimated 20% of 
blood products administered to patients globally.1 An estimated 50% of patients require a blood 
transfusion undergoing cardiac surgery and bleeding inevitably occurs from invasive cardiothoracic 
procedures requiring an open-approach.2 Furthermore, an estimated 25% of blood product transfusions 
may be considered inappropriate in coronary artery bypass graft (CABG) procedures.3  In an effort to 
minimize allogeneic blood transfusions, many clinicians and researchers have identified best practices 
for blood conservation strategies as well as studied factors independently predictive of bleeding and 
patients requiring RBC transfusion.4-7  
Last updated in 2011, the Society of Thoracic Surgeons (STS) provides evidence-based 
recommendations for preoperative and perioperative strategies to minimize blood loss and the need for 
blood transfusion.4 These recommendations include discontinuation of antiplatelet and anticoagulant 
agents prior to surgery, red blood cell volume optimization (i.e. erythropoietin use to increase 
hematocrit (HCT), administration of intraoperative medications that reduce blood loss (i.e. intravenous 
ε-aminocaproic acid (EACA) or tranexamic acid), and specific recommendations of when to use 
allogeneic blood products and factor concentrates as well as many other guiding principles. Even when 
STS’s recommendations are followed, several factors are independently associated with bleeding and 
RBC transfusion in invasive cardiac surgery that are non-modifiable: older age, female gender, lower 
weight, and emergent or complex operations (redo procedures, operations other than CABG, aortic 
surgery, etc.).6-7  
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While a large body of evidence provides guidance on predictive factors associated with bleeding 
and RBC transfusion, little evidence has been published on factors associated with the use of fresh 
frozen plasma (FFP) and prothrombin complex concentrates. STS does provide guidance to administer 
FFP when patients experience serious bleeding in the context of multiple or single coagulation factor 
deficiencies when safer fractionated products are not available.4 In addition, FFP should be included as 
part of massive transfusion protocols when substantial amounts of red blood cells (RBCs) are 
administered, which is recommended in massive transfusion protocols regardless of procedure type.4 
On the opposite end of the spectrum, prophylactic use of FFP in cardiac surgery is not recommended, 
because it does not reduce blood loss or RBC transfusion.8-9 Thus, the focused use of FFP only in 
situations of excessive bleeding have resulted in limited research performed to assess factors predicting 
its use intraoperatively. 
Since STS last updated its guidelines on blood conservation strategies in 2011, the society does 
not provide specific guidance on prothrombin complex concentrate (PCC) versus FFP use, except for the 
urgent reversal of warfarin prior to the procedure.4 The European Society of Anaesthiologists 
recommend the use of PCC intraoperatively in the presence of an elevated bleeding tendency and 
prolonged clotting time, where the adoption of PCC products in clinical practice has increased.5 Mixed 
evidence supports the use of PCC to mitigate blood loss in cardiac surgery, and no studies have been 
published comparing the factors predictive of using FFP versus PCC in cardiac surgery.10-15 With surgery 
teams having access to both FFP and/or PCC, knowing the factors predicting their administration will 
assist in establishing best practices for their use and improve future prescribing.   
Therefore, the purpose of this study was to describe the utilization pattern of four-factor 
prothrombin complex concentrate (4PCC) and fresh frozen plasma (FFP) use intraoperatively in coronary 
artery bypass graft (CABG) and valve surgeries requiring cardiopulmonary bypass (CPB) and evaluate 
factors associated with use of 4PCC or FFP intraoperatively in CABG and valve surgeries requiring CPB.  
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METHODS 
DESIGN AND SETTING 
This retrospective, observational, cohort study identified all CABG, valve repair, and valve 
replacement surgeries from March 2014 to April 2016 at Houston Methodist Hospital (HMH), Houston, 
Texas. HMH and University of Houston Institutional Review Boards approved the study design and 
procedures, and HMH waived patient consent for this expedited study. In the Texas Medical Center, 
HMH is an academic, quaternary care institution with 1,119 licensed beds that serves the greater 
Houston area and performs more than 1,000 CABG and valve procedures annually.  
DATA SOURCES AND COLLECTION PROCEDURE 
The data sources for this study included claims data from Vizient, institutional electronic health 
records (EHR), and clinical measures from Society of Thoracic Surgeons (STS). Vizient clinical database 
and resource manager was used to identify all CABG and valve procedures performed on patients 
admitted from March 2014 to April 2016 at Houston Methodist Hospital (HMH). The Vizient 
membership includes academic health systems from across the country, and these health systems 
developed the Quality and Accountability Study in order to gather objective, data-driven measures for 
comparing health systems. The Vizient database provides demographic and claims data as well as 
proprietary severity of illness and risk adjustment models.  
The EHR anesthesia manager was used to gather intraoperative clinical measures for patients 
receiving CABG and valve surgeries, and preoperative and postoperative measures were gathered from 
the EHR that were unavailable from STS. From the EHR, the study investigators gathered clinical 
measures including vital signs, laboratory results, drug exposures and doses, blood product 
administration, documented blood loss, and timing of these events. These data elements were collected 
24 hours prior to the procedure from the EHR, intraoperatively from the anesthesia records, and 24 
hours post-operatively from the EHR. Laboratory values collected were hemoglobin, platelets, 
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fibrinogen, serum creatinine, INR, bilirubin, albumin, and thromboelastography. All anticoagulant and 
procoagulant agents administered were collected during the aforementioned time windows. 
The STS National Database was established in 1989 as an initiative for quality improvement and 
patient safety among cardiothoracic surgeons. The STS Database contains a large number of clinical, 
administrative, and diagnostic data elements available to institutions contributing to the dataset. The 
patient list generated from Vizient was used to identify patients from STS. Variables utilized from the 
STS database included surgeon, body mass index (BMI), surgery type, CABG count, previous 
cardiovascular surgeries, patient status preoperatively, comorbidities, anticoagulation prior to surgery, 
preoperative lab values, and cardiopulmonary bypass time.  
The 4PCC exposures were identified from charge claims extracted from the Vizient database and 
validated from the EHR. A random sample of patients was independently reviewed by two study 
investigators to ensure the validity of the data collected. Any discrepancies were validated by a third 
study investigator.   
STUDY POPULATION  
Patients identified from Vizient included the following ICD-9 procedure codes: 3610, 3611, 3612, 
3613, 3614, 3615, 3616, 3619, 351, 3511, 3512, 3513, 3514, 352, 3521, 3522, 3523, 3524, 3525, 3526, 
3527, 3528, 3531, 3532, 3533, and 3732. ICD-10 procedure codes used to identify patients are found in 
the Appendix (Tables 1-3). The study sample included patients 18 years of age or older receiving open-
chest CABG, valve repair, and/or valve replacement requiring CPB. All elective, urgent, and emergent 
procedures were included in the study. Patients who received other cardiac procedures during the CABG 
or valve procedure were excluded (i.e. adult congenital cardiac operation, free wall rupture repairs, 
cardiac tumor removal etc.). Patients receiving both FFP and 4PCC intraoperatively or factor 
concentrates other than 4PCC and FibC intraoperatively were excluded from the analysis. Patients 
documented as receiving 4PCC or FFP in the operative anesthesia record were included intervention 
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groups. Additional exclusion criteria were patients with an unresponsive neurological state prior to 
procedure, refusal of blood products, previous aortic procedures, resuscitation prior to procedure, robot 
use during the procedure, circulatory arrest/cooling performed during procedure, pulmonary valve 
replacement, patients who did not transfer to ICU after care, patients who received factor concentrate 
within 24 hours preoperatively, or received a factor concentrate within 24 hours post-procedure.  
CONCEPTUAL FRAMEWORK: ANDERSEN BEHAVIORAL MODEL 
The Anderson Behavioral Model (ABM) of health services research was applied in this study to 
evaluate factors associated with utilization of 4PCC and FFP intraoperatively during cardiac surgery. ABM 
was developed almost 50 years ago to characterize why families use specific health services and 
facilitate the identification of inequitable services.16,17 Since the creation of ABM, the theory continues 
to receive modifications that enhance its ability to determine what factors influence healthcare 
utilization.14 Noteworthy enhancements to the model include ABM extending to individuals from 
families, incorporation of system concepts such as healthcare policies, application to consumer 
satisfaction in the 1970s, and the most updated model includes feedback loops, which gives ABM 
directionality in relation to the factors influencing a health outcome.16-19 ABM has been applied to 
hundreds of different settings including medication prescribing and factors that may predict prescribing 
and/or utilization of specific medications.16 
Three principal components comprise ABM: predisposing factors, enabling factors, and need 
factors. Predisposing factors consist of individual characteristics existing prior to the health service 
utilization and/or the outcome interest and are not directly responsible for health service use. Common 
predisposing factors include demographic variables such as age, sex, and race, which were included in 
our model. Enabling factors facilitate or impede the use of a health service. Enabling factors used to 
determine 4PCC or FFP administration included the surgeon and the nature of the care (elective, urgent, 
emergent).16 
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Finally, need factors represent more immediate determinants of using a health service. Need 
factors consist of an array of variables such as diagnostic results, laboratory values, comorbidities, and 
functional status. Need factors included in our model included many comorbidities, pertinent laboratory 
values prior to surgery, medications affecting coagulation pre and postoperatively, and other factors 
that influence the patients’ coagulation status intraoperatively.16   
SURGICAL PROCEDURE AND OPERATIVE MANAGEMENT 
CABG and valve procedures are conducted via a median sternotomy approach. CPB is initiated in 
a routine manner involving cannulation of the right atria, vena cava, or femoral vein to oxygenate blood 
withdrawn from the body and returning the oxygenated blood to the ascending aorta. Anticoagulants 
and antiplatelets are discontinued as appropriate prior to surgery—if the planned case is elective. 
Anticoagulation generally resumes within 24 to 48 hours post-surgery unless contraindicated to resume 
therapy (i.e. active bleeding). At our institution, intravenous heparin is administered at doses of 300 to 
400 units per kg to maintain an activated clotting time (ACT) above 450 seconds prior to the procedure. 
After the induction of anesthesia, patients receive a standard infusion of intravenous ε-aminocaproic 
acid (EACA) 10 gram bolus, followed by a 10 gram infusion during the procedure, and a 5 gram bolus at 
the end of the surgery.  When CPB is ceased, protamine sulphate is administered 1 mg per 100 units of 
heparin given during the procedure. Patients with prolonged ACT after surgery will received additional 
protamine as necessary for reversal of heparin effects. After the reversal of heparin, the anesthesiologist 
and surgery team will visually inspect the surgical field for major bleeding and/or microvascular bleeding 
to determine if blood products—RBCs, FFP, platelets, and/or factor concentrates (4PCC and/or FibC)—
are warranted as well as perform thromboelastography (TEG) if necessary. The TEG results are used to 
guide the administration of allogeneic blood products. Thus, the various modalities used to cease 
bleeding and restore hemostasis are individualized. The use and administration of factor concentrates 
and allogeneic blood products is not protocolized at our institution, and providers may use either 
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allogeneic blood products or factor concentrates as per their clinical judgment. Other elements 
considered prior to administration of these treatment modalities includes prothrombin time, activated 
partial thromboplastin time, platelet count, hemoglobin, and hemodynamics. After open-chest CABG 
and valve procedures, patients are transferred to the cardiovascular intensive care unit for 
management.  
The 4PCC product used exclusively at HMH is Kcentra (CSL Behring; Marburg, Germany), and the 
FibC product used exclusively is RiaSTAP (CSL Behring; Marburg, Germany). Kcentra was approved in 
April of 2013, and RiaSTAP was approved in January of 2009. The use of these products intraoperatively 
began in January to February 2014 for CABG and valve surgeries. Kcentra is supplied in 20 mL vials with 
approximately 500 units of Factor IX. The product is reconstituted with 2 diluents supplied with the 
medication. Kcentra is administered intraoperatively slow intravenous push following the maximum rate 
of the package insert of 210 units per minute. RiaSTAP is supplied in 50 mL vials with 900 to 1300 mg of 
lyophilized fibrinogen concentrate powder. RiaSTAP is reconstituted with 50 mL of sterile water and is 
administered slow intravenous push as recommend by the package insert.20,21 
STUDY VARIABLES AND DEFINITIONS 
 This study evaluated factors associated with use of 4PCC or FFP intraoperatively in CABG and valve 
surgeries requiring CPB. Three models were created to determine the predictive factors of administering 
4PCC or FFP intraoperatively. The dependent variable in each of these logit models was the dichotomous 
exposure of 4PCC (0=no, 1=yes), FFP (0=no, 1=yes), or 4PCC versus FFP (FFP=0, 4PCC=1).  
As previous described, the independent variables were selected based on the Andersen Behavioral 
Model and divided into the three primary categories of the model: predisposing, enabling, and need 
factors. These included: 
Predisposing factors 
1. Age: Age was modeled continuously by year of age. 
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2. Sex: Sex was categorized for male (0) and female (1).  
3. Race: Self-reported race was categorized as white (0), black (1), Asian (2), and other (3). 
Enabling factors 
1. Surgeon: Surgeons performing the surgeries were categorized based on each individual with one 
combined variable for surgeons performing surgeries less often (surgeon other).  
2. Preoperative status (emergent/urgent or elective): Preoperative status was dichotomized as 
elective (0) or emergent/urgent (1).  
Need factors 
1. Combined CABG + valve procedure: Patients who received CABG plus a valve surgery were 
categorized as 1 if yes or 0 if no. 
2. Previous open chest procedure: Patients with previous open chest procedures were categorized 
as 1 if yes or 0 if no. 
3. Body mass index (BMI): BMI was modeled as continuous variable in kg/m2. 
4. Comorbidities were based on documentation from STS and dichotomized as 1 if present and 0 if 
not. 
a. Arrhythmia: Patient was considered as having an arrhythmia if the patient had a history 
of a cardiac rhythm disturbance before the start of the operative procedure which 
includes the institution of anesthetic management. 
b. Coronary artery disease (CAD): Patient was considered as having coronary artery 
anatomy and/or disease if documented and available prior to surgery. 
c. Cerebrovascular disease (CVD): Patient was considered to have CVD if any of the 
following were present prior to the procedure:  
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i. Stroke: Stroke is an acute episode of focal or global neurological dysfunction 
caused by brain, spinal cord, or retinal vascular injury as a result of hemorrhage 
or infarction, where the neurological dysfunction lasts for greater than 24 hours. 
ii. TIA: Defined as a transient episode of focal neurological dysfunction caused by 
brain, spinal cord, or retinal ischemia, without acute infarction, where the 
neurological dysfunction resolves within 24 hours. 
iii. Noninvasive or invasive arterial imaging test demonstrating >=50% stenosis of 
any of the major extracranial or intracranial vessels to the brain. 
iv. Previous cervical or cerebral artery revascularization surgery or percutaneous 
intervention. This does not include chronic (nonvascular) neurological diseases 
or other acute neurological insults such as metabolic and anoxic ischemic 
encephalopathy. 
d. Diabetes mellitus (DM): Patient was considered to have DM if diagnosed and/or treated 
by a healthcare provider in the past. 
e. Dyslipidemia: If the patient had a history of dyslipidemia that was diagnosed and/or 
treated by a physician. 
i. National Cholesterol Education Program (NCEP) criteria include documentation 
of the following: 
1. Total cholesterol >200 mg/dL (5.18 mmol/L); or 
2. LDL >=130 mg/dL (3.37 mmol/L); 
3. HDL <40 mg/dL (1.04 mmol/L) in men and <50 mg/dL (1.30 mmol/L) in 
women; 
4. Currently receiving antilipidemic treatment. 
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f. Heart failure (HF): Patient has a history of heart failure occurring more than 2 weeks 
prior to current episode of care. 
g. Hypertension (HTN): If the patient had a current diagnosis of hypertension defined by 
any 1 of the following: 
i. History of hypertension diagnosed and treated with medication, diet, and/or 
exercise. 
ii. Prior documentation of blood pressure >140 mm Hg systolic and/or 90 mm Hg 
diastolic for patients without diabetes or chronic kidney disease, or prior 
documentation of blood pressure >130 mm Hg systolic or 80 mm Hg diastolic on 
at least 2 occasions for patients with diabetes or chronic kidney disease. 
iii. Currently undergoing pharmacological therapy for treatment of hypertension. 
h. Immunocompromised: Indicates whether the patient was immunocompromised due to 
immunosuppressive medication therapy within 30 days preceding the operative 
procedure or existing medical condition. This includes, but is not limited to systemic 
steroid therapy, anti-rejection medications and chemotherapy. This does not include 
topical steroid applications, one time systemic therapy, inhaled steroid therapy or pre-
procedure protocol. 
i. Liver dysfunction: Patient had a history of hepatitis B, hepatitis C, cirrhosis, portal 
hypertension, esophageal varices, chronic alcohol abuse or congestive hepatopathy, 
excludes NASH in the absence of cirrhosis. 
j. History of myocardial infarction (MI): The patient had at least one documented previous 
myocardial infarction at any time prior to this surgery. 
k. Peripheral artery disease (PAD): Patient had a history of peripheral arterial disease 
(includes upper and lower extremity, renal, mesenteric, and abdominal aortic systems). 
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l. Pneumonia (PNA): Patient was considered to have a history of PNA if the patient had a 
recent (within 30 days) or remote (more than 30 days) history of PNA. 
5. Anticoagulation received within 48 hours of procedure: Patients who received anticoagulation 
within 48 hours of procedure that was an intravenous and/or subcutaneous anticoagulant. 
6. Antiplatelet received within 5 days of the procedure: This variable indicated whether a patient 
received an antiplatelet within 5 days preceding surgery. 
7. Aspirin use prior to the procedure: This variable indicated whether a patient received aspirin or 
Ecotrin within 5 days preceding surgery. 
8. Categorized central venous pressure (CVP): Patient’s central venous pressure was documented 
immediately prior to incision time and categorized as 0-3 (1), 4-9 (0), 10-15 (2), and > 15 (3).   
9. Hematocrit (HCT) % prior to the procedure: HCT was modeled as a continuous variable and 
gathered within 24 hours of the procedure.  
10. Left ventricular ejection fraction (LVEF) prior to the procedure: Last documented LVEF prior to 
induction of anesthesia. LVEF was modeled as a continuous variable.  
11. Dichotomized platelet count: The platelet count closest to the date and time prior to surgery. 
This variable was dichotomized to platelets greater than or equal to 150 (1) and less than 150 
109/L (0).   
12. Serum creatinine, mg/dL (SCr) prior to the procedure: The SCr closest to the date and time prior 
to surgery and was modeled continuously. 
13. Cell save use (units): The documented amount of cell saver units recycled intraoperatively and 
modeled continuously.  
14. Cardiopulmonary bypass (CPB) time (min): The total number of minutes that systemic return 
was diverted into the CPB circuit and returned to the systemic system. 
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15. Intraoperative antithrombin III use: Documented intraoperative administration of antithrombin 
III, 1 if given and 0 if not given. 
16. Intraoperative desmopressin use: Documented intraoperative administration of desmopressin, 1 
if given and 0 if not given. 
17. Intraoperative ε-aminocaproic acid (EACA) use: Documented intraoperative administration of 
EACA, 1 if given and 0 if not given. 
Variables represented in the patient’s baseline characteristics but not included in the models were 
cancer, chronic lung disease, hemodialysis, inotrope administration prior to procedure, intraoperative 
fibrinogen concentrate, and aortic cross-clamp time (ACT). Cancer, chronic lung disease, intraoperative 
fibrinogen concentrate, and inotrope administration prior to procedure were excluded due to the small 
sample size in the study groups. SCr allowed for patients undergoing hemodialysis to be indirectly 
controlled for in addition to mild and moderate chronic kidney disease. Finally, aortic cross-clamp time 
and surgery duration were strongly collinear to CPB and not included in the model.     
STATISTICAL ANALYSIS 
Descriptive statistics and bivariate analysis were used to compare the study samples: patients 
exposed to 4PCC, patients exposed to FFP, and patients not exposed to 4PCC or FFP. Two-tailed bivariate 
analysis was performed using student’s t-test for continuous parametric data, Wilcoxon rank-sum test 
for continuous non-parametric data, and chi-square test or fisher’s exact for proportional data. A p-
value of < 0.05 was accepted as indicating a statistical significance. Comparisons across the 3 study 
groups were not performed, because differences across the study groups were not of interest.  
Multivariable logistic regression analyses were used to determine the predictors of 
intraoperative use of 4PCC or FFP. In the 4PCC model, patients who received FFP intraoperatively were 
excluded and vice versa for the FFP model. In addition, a multivariable logistic model was created that 
included only FFP and 4PCC exposed patients to determine what factors predicted 4PCC versus FFP use. 
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In the model comparing FFP and 4PCC, a backward elimination function was used to determine the 
predictive factors of using of 4PCC versus FFP administered intraoperatively. Backward elimination was 
chosen to create a parsimonious model due to the smaller sample size including only FFP and 4PCC 
patients.22 Compared to other variable selection techniques in regression, backward elimination offers 
the advantage of decreasing the likelihood of omitting important negatively confounded sets of 
variables, because all variables are included in the initial model.22,23 In addition, backward elimination 
function performs as well as other stepwise/elimination functions based on simulation studies.21 All 
confounding variables found to be significant at p-value < 0.2 in a backward elimination function were 
included model comparing 4PCC to FFP.22,23 
The dependent variable for these models were dichotomous variables of FFP (0=no exposure, 
1=exposure), 4PCC (0=no exposure, 1=exposure), and FFP versus 4PCC (0=FFP, 1=4PCC), respectively. 
Independent variables were selected a priori based on the ABM model of health service utilization 
(predisposing, enabling and need factors). The mathematical expression of the logistic regression model 
is:  
log (𝑝/1 – 𝑝)= 𝛽0 + 𝛽1 𝑋1 + 𝛽2 𝑋2 + … + 𝛽𝑘 𝑋𝑘 
Where X1....... Xk were predictor variables (predisposing, enabling and need variables), and p was the 
probability of the occurrence of the exposure—FFP or 4PCC. Beta coefficients were exponentiated to 
provide odds ratios in order to interpret factors associated with FFP or 4PCC use.  
A p-value of less than 0.05 was accepted as indicating a statistical significance in the 
multivariable models and bivariate statistical tests. The discrimination of each multivariable model was 
determined by calculating the C-statistic, and the calibration of the model was determined by 
performing the Hosmer-Lemeshow test. A p-value of greater than 0.05 for the Hosmer-Lemeshow test 
indicates a good fit. Statistical analyses were performed using SAS 9.3, SAS Institute, Cary, NC. 
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RESULTS 
UTILIZATION OF 4PCC AND FFP USE IN CARDIAC SURGERY 
During the study timeframe, 690 patients (70.2%) did not receive FFP or 4PCC intraoperatively 
(control), 166 patients (16.9%) received 4PCC only, 68 patients (6.9%) received FFP only, and 58 (5.9%) 
received both 4PCC and FFP intraoperatively. After excluding patients who received both FFP and 4PCC, 
a total of 924 patients were included in the analysis of the 2,105 patients who underwent CABG and/or 
valve surgery (Figure 1). The median dose of 4PCC administered to patients was 500 U (9.0 ± 5.8 U/kg), 
and the median dose of FFP was 2 U (5.9 ± 3.4 mL/kg). More patients in the control and FFP groups 
underwent CABG alone (Control: 329 (56.8%); FFP: 33 (48.5%), and less patients in the control and FFP 
groups had valve procedures alone compared to the 4PCC group (Control: 247 (35.8%); FFP: 27 (39.7%).  
The control group also had significantly less repeat open-chests compared to the FFP and 4PCC groups 
(Control: 68 (9.9%); FFP: 14 (20.6%), 4PCC: 40 (24.1)). In addition, the control group had significantly 
shorter surgeries, CPB time, aortic cross-clamp time (ACT), and required less cell saver units compared 
to the FFP and 4PCC groups, while the FFP and 4PCC groups did not differ on any of the aforementioned 
measures (Table 1).  
PREDICTORS OF 4PCC USE IN CARDIAC SURGERY 
Several predictor factors were associated with receiving 4PCC compared to the control (Table 2). 
The only predisposing factor associated with receiving 4PCC was age (years) (OR: 1.03; 95% CI: 1.01-
1.05), and no enabling factors were associated with receiving 4PCC compared to the control. Need 
factors that increased the odds of receiving 4PCC compared to the control were INR (OR: 16.1; CI: 4.0-
64.2), cell saver use (units) (OR: 1.82; CI: 1.49-2.21), CPB time (min) (OR: 1.02; CI: 1.01-1.02), and 
desmopressin use (OR: 3.51; CI: 2.21-5.57). Need factors associated with a decrease in the odds of 
receiving 4PCC compared to the control included BMI (OR: 0.94; CI: 0.90-0.98), HCT (%) (OR: 0.91; CI: 
0.87-0.96), platelets greater than 150 109/L (OR: 0.55; CI: 0.32-0.95), cardiac arrhythmia (OR: 0.55; CI: 
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0.32-0.95), dyslipidemia (OR: 0.49; CI: 0.28-0.85), and EACA intraoperative use (OR: 0.34; CI: 0.14-0.81). 
The c-statistic yielded for this model was 0.85, and the Hosmer-Lemeshow test was not significant 
(p=0.07).  
PREDICTORS OF FFP USE IN CARDIAC SURGERY 
No predisposing factors were predictive of using FFP compared to the control group. Of the 
enabling factors in the regression model, patients undergoing an emergent procedure was significantly 
associated with the administration of FFP compared to the group (OR: 2.23; CI: 1.12-4.48) (Table 3). 
Need factors associated with an increase in the odds of receiving FFP compared to the control were 
patients with a history of cerebrovascular disease (CVD) (OR: 2.12; CI: 1.11-4.08) and cell saver use 
(units) (OR: 1.42; CI: 1.10-1.82). The c-statistic yielded for this model was 0.78, and the Hosmer-
Lemeshow test was not significant (p=0.483). 
PREDICTORS OF 4PCC COMPARED TO FFP USE IN CARDIAC SURGERY 
Of the 34 variables included in the backward elimination model, 14 variables stayed in the 
regression model (Table 4). No predisposing or enabling factors were significantly associated with 
patients receiving 4PCC or FFP. Patients were more likely to receive 4PCC compared to FFP with each 
unit increase in cell saver use (OR: 1.32; CI: 1.08-1.72), if desmopressin was administered 
intraoperatively (OR: 2.26; CI: 1.14-4.48), and if the patient had HTN (OR: 2.58; CI: 1.01-6.60). Factors 
decreasing the likelihood of receiving 4PCC compared to FFP were patients that had dyslipidemia (OR: 
0.43; CI: 0.19-0.99), liver dysfunction (OR: 0.16; CI: 0.06-0.48), and HCT (%) (OR: 0.92; CI: 0.86-0.98). The 
c-statistic yielded for this model was 0.75, and the Hosmer-Lemeshow test was not significant (p=0.842). 
DISCUSSION 
 This retrospective cohort study evaluated the utilization of 4PCC and FFP intraoperatively and 
predictive factors for prescribing 4PCC and FFP in patients that underwent CABG and/or valve surgery 
requiring CPB. Of the 924 patients that met the study’s inclusion criteria, 166 patients (17.9%) received 
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only 4PCC intraoperatively and 68 patients (7.4%) received only FFP intraoperatively. The median dose 
of 4PCC administered to patients was 500 U (9.0 ± 5.8 U/kg), and the median dose of FFP was 2 U (5.9 ± 
3.4 mL/kg). Based on the Andersen Behavioral Model, predisposing, enabling, and need factors 
associated with prescribing 4PCC and FFP intraoperatively were identified from 3 multivariable logistic 
regression models. 
 Currently, no published studies describe the proportion of patients receiving 4PCC or other 
factor concentrates in patients that underwent CABG and/or valve surgery requiring CPB. Data on the 
prescribing rates comparing PCC and FFP are largely unavailable at institutions in the United States, 
since PCC administration is only indicated for the urgent reversal of warfarin when used in surgery. 
Furthermore, the STS guidelines for blood management in cardiac surgery were last updated in 2011, 
and the paucity of new literature published has not been incorporated into their recommendations.4,10-15 
In Europe, the Society of Anaesthiology also recommends the use of PCC intraoperatively in the 
presence of an elevated bleeding tendency and prolonged clotting time, where the adoption of PCC 
products in clinical practice has increased.5 The majority of clinical trials assessing PCC use in cardiac 
surgery have occurred in European countries, which supports the more widespread adoption in Europe 
compared to the United States.10-15  
While the utilization of PCC during cardiac surgery is unknown in the United States, all isolated 
CABG procedures requiring CPB reported in the STS database were evaluated in 2008 and found 19.3% 
(95% CI: 19.1%-19.6%) of patients were exposed to FFP intraoperatively. In our study, 29.7% of patients 
were exposed to FFP and/or 4PCC (including patients who received both 4PCC and FFP excluded from 
the analysis) intraoperatively or within 24 hours postoperatively.24 Also, our study included patients that 
received valve surgery and CABG plus valve surgeries, which require more blood transfusions compared 
to isolated CABG. As global and national assessments of blood conservation efforts are evaluated in the 
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future, researchers need to incorporate the utilization of factor concentrates in order to accurately 
compare institutions. 
 The doses of 4PCC and FFP administered to patients in our study were similar based on the 
Factor IX component. The amount Factor IX in 2 U of FFP ranges between 300 to 500 U, and the median 
dose of 4PCC patients received in our study based on the Factor IX component was 500 U.25 Compared 
to other published studies, our patients received lower doses of PCC. In a retrospective study comparing 
3PCC to FFP in CABG and valve surgery, the median 3PCC dose was 1,500 U, and median dose of FFP was 
2 U—this study did not report weight-based doses.12 Another retrospective study comparing 4PCC to FFP 
during pulmonary endarterectomy with hypothermic circulatory arrest used a dose of 15 U/kg of 4PCC 
and 15 mL/kg of FFP.13 The labeling for Kcentra® recommends a dosing range of 25 to 50 U/kg for the 
reversal of acute major bleeding based on the patient’s INR.20 The upper end of this dosing range has 
resulted in fatal patient cases being reported, and why 4PCC contains a Black Box warning for patients 
with thromboembolic disease.20,26 With PCC becoming more widely adopted in cardiac surgery, the 
optimal dosing strategy for patients remains unknown and requires further investigation to ensure 
effective and safe doses are selected. 
Predictive factors positively associated with 4PCC use compared to the control group were 
expected: age, INR, cell saver use, CPB time, and desmopressin administration intraoperatively. Of the 5 
measures predictive of 4PCC use, the first 4 have been previously found to be associated with blood 
transfusion.4-7 Desmopressin was a predictive factor of 4PCC administration likely because of the longer 
CPB time and greater proportion of uremic ESRD patients resulting in increased platelet dysfunction.27 
Similar to the predictive factors positively associated 4PCC use, the negatively associated factors were 
anticipated and previously shown to be inversely associated with blood transfusion: BMI, HCT, platelets 
> 150 109/L, and EACA intraoperative use.4-7 Two unanticipated factors negatively associated with the 
use of 4PCC were patients with a history of cardiac arrhythmia and dyslipidemia. Providers may have 
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been less likely to administer 4PCC in this patient population due to the clotting risk associated with 
4PCC and these comorbidities increasing the risk of thromboembolic events. 
 Comparing the predictive factors of administering FFP to the control, predictive factors 
positively associated with FFP use were patients requiring an emergent procedure, history of CVD, and 
the number of cell saver units used. Emergent procedures and cell saver use are independently 
associated with blood product transfusions, and these factors were expected to be associated with FFP 
use.4-7 The significant association with patients having a history of CVD with FFP administration warrants 
further investigation and previously not shown in other studies.  
 The multivariable model assessing predictive factors associated with the use of 4PCC versus FFP 
found several important relationships with respect to need factors. Patients were more likely to receive 
4PCC versus FFP as the number of cell saver units used increased, if desmopressin was administered 
intraoperatively, and if a patient had a history of HTN.  While no significant differences were found in 
the EBL of patients receiving 4PCC versus FFP, it appears 4PCC was given preferentially for patients who 
required more cell saver use. As previously mentioned, the increased desmopressin use in the 4PCC 
group may be attributed to the longer CPB time and greater proportion of uremic ESRD patients, which 
may cause greater platelet dysfunction.27 Predictive factors negatively associated with using 4PCC were 
patients with a history of dyslipidemia, liver dysfunction, and HCT. As previously hypothesized, FFP may 
have been given preferentially to patients with dyslipidemia due to the increase risk of thromboembolic 
events with 4PCC. FFP contains additional coagulation factors not in 4PCC such Factor XIII and XI and 
may explain why patients with liver dysfunction were more likely to receive FFP.25 As HCT increased, 
patients were less likely to have received 4PCC compared to FFP. This inverse relationship may be due 
patients requiring more rapid reversal of coagulopathy with lower HCT and why 4PCC was given in this 
scenario. Of note, the surgeons who performed the procedures were not associated with the use of FFP 
or 4PCC in any of the multivariable models.  
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STRENGTHS AND LIMITATIONS 
This study provides the first assessment of predictive factors associated with the administration 
of 4PCC versus FFP during cardiac surgery. Other strengths include the utilization of the STS database, 
which researchers frequently use to evaluate cardiac surgery quality and safety. This study also collected 
many clinical variables to determine the relationship with 4PCC and FFP use. Relative to other studies, 
this study included a large number of patients exposed to 4PCC.  
Like all retrospective studies, this study has limitations. While this study included many 
demographic and clinical variables in the multivariable models, other unmeasured factors in surgery 
may influence prescribing of 4PCC and/or FFP. The multivariable models evaluated associations and not 
causal relationships. FibC prescribing could not be isolated from 4PCC versus FFP multivariable analysis, 
because only 1 patient received FFP. Thus, this FibC variable was excluded from the model. Also, this 
study did not have access to a robust number of predisposing and enabling factors, which may influence 
the selection of 4PCC and/or FFP. Finally, this study represents a single institution’s practices and needs 
to be carefully considered before extrapolating to other institutions. 
CONCLUSION 
This retrospective, single-institution study found an increasing number of patients receiving 
4PCC compared to FFP to mitigate blood loss in cardiac surgery. Based on the Andersen Behavioral 
model, predictive factors of administering 4PCC and FFP vary in cardiac surgery, and these factors offer 
insight into patients’ comorbidities and clinical variables associated with their use. Future studies need 
to explore the relationship between the predictive factors associated with 4PCC or FFP use and the 
clinical outcomes in these specific patient populations.  
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CHAPTER III: 
EFFECTIVE AND SAFETY OF 4PCC COMPARED TO FFP IN CARDIAC 
SURGERY 
INTRODUCTION 
 
Major bleeding during and post open-heart surgery requiring cardiopulmonary bypass (CPB) 
may result in increased morbidity and mortality, re-exploration post-surgery, and require considerable 
blood product transfusions.1-15 Acute blood loss requiring transfusion of blood products (i.e. red blood 
cells (RBCs) or fresh frozen plasma (FFP)) is associated with increased risk of infection, transfusion-
related lung injury (TRALI), transfusion-associated circulatory overload (TACO), acute renal failure, 
thromboembolic events, transfusion-related immunomodulation (TRIM), and allergic/anaphylactic 
reactions.1-15 In addition, the process of ordering, receiving, and administering blood products may 
cause delays in time critical treatment of an acute blood loss.16 
The aforementioned adverse effects associated with blood product transfusions has led 
providers to seek other alternative therapies to mitigate blood transfusion requirements during 
procedures. Initially approved for the reversal of acute major bleeding caused by vitamin K antagonist 
therapy, four-factor prothrombin complex concentrate (4PCC) contains a high concentration of 
lyophilized clotting factors II, VII, IX, X, and protein C and S and rapidly reverses coagulopathy in specific 
scenarios.17 4PCC offers several benefits when used to minimize bleeding compared to FFP that include 
a faster onset, increased potency, small volume, and ability to administer more quickly due to quick 
reconstitution.16 While 4PCC may offer a useful alternative to decrease perioperative bleeding, these 
products also carry risks including thromboembolic events, infusion-related reactions, hypotension, 
angioedema, and cost.16,17 An ex vivo study comparing different permutations of factor concentrates 
products versus allogeneic blood products found factor concentrates to have a more optimal hemostasis 
profile following cardiac surgery.18 A small number of experimental and clinical studies have supported 
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the use of 3-factor prothrombin complex concentrates (3PCC) and other factor concentrate products to 
minimize bleeding and decreasing the need for blood product transfusions during cardiovascular 
procedures.19-24  
Since STS last updated its guidelines on blood conservation strategies for cardiac surgery in 
2011, the society does not provide specific guidance on the use of PCC versus FFP, except for the urgent 
reversal of warfarin prior to the procedure.20 The European Society of Anaesthiologists recommend the 
use of PCC intraoperatively in the presence of an elevated bleeding tendency and prolonged clotting 
time, where the adoption of PCC products in clinical practice has increased.21 With surgery teams having 
access to both FFP and/or PCC, limited comparative data exists regarding 4PCC and  FFP in CABG and 
valve surgery.22-27 The proposed study will provide a significant contribution to the literature, because it 
offers a real-world analysis regarding the safety and effectiveness of 4PCC compared to FFP in CABG and 
valve procedures. Only one other nonrandomized study has been published assessing a 3PCC product 
administered to normocoaguable patients receiving CABG and/or valve procedures in an Italian hospital, 
and no large randomized or nonrandomized studies have been published assessing 4PCC in CABG and 
valve procedures.24 
METHODS 
DESIGN AND SETTING 
This retrospective, observational, cohort study identified all CABG, valve repair, and valve 
replacement surgeries from March 2014 to April 2016 at Houston Methodist Hospital (HMH), Houston, 
Texas. HMH and University of Houston Institutional Review Boards approved the study design and 
procedures, and HMH waived patient consent for this expedited study. In the Texas Medical Center, 
HMH is an academic, quaternary care institution with 1,119 licensed beds that serves the greater 
Houston area and performs more than 1,000 CABG and valve procedures annually.  
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DATA SOURCES AND COLLECTION PROCEDURE 
The data sources for this study included claims data from Vizient, institutional electronic health 
records (EHR), and clinical measures from Society of Thoracic Surgeons (STS). Vizient clinical database 
and resource manager was used to identify all CABG and valve procedures performed on patients 
admitted from March 2014 to April 2016 at Houston Methodist Hospital (HMH). The Vizient 
membership includes academic health systems from across the country, and these health systems 
developed the Quality and Accountability Study in order to gather objective, data-driven measures for 
comparing health systems. The Vizient database provides demographic and claims data as well as 
proprietary severity of illness and risk adjustment models.  
The EHR anesthesia manager was used to gather intraoperative clinical measures for patients 
receiving CABG and valve surgeries, and preoperative and postoperative measures were gathered from 
the EHR that were unavailable from STS. From the EHR, the study investigators gathered clinical 
measures including vital signs, laboratory results, drug exposures and doses, blood product 
administration, documented blood loss, and timing of these events. These data elements were collected 
24 hours prior to the procedure from the EHR, intraoperatively from the anesthesia records, and 24 
hours post-operatively from the EHR. Laboratory values collected were hemoglobin, platelets, 
fibrinogen, serum creatinine, INR, bilirubin, albumin, and thromboelastography. All anticoagulant and 
procoagulant agents administered were collected during the aforementioned time windows. 
The STS National Database was established in 1989 as an initiative for quality improvement and 
patient safety among cardiothoracic surgeons. The STS Database contains a large number of clinical, 
administrative, and diagnostic data elements available to institutions contributing to the dataset. The 
patient list generated from Vizient was used to identify patients from STS. Variables utilized from the 
STS database included surgeon, body mass index (BMI), surgery type, CABG count, previous 
cardiovascular surgeries, patient status preoperatively, comorbidities, anticoagulation prior to surgery, 
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preoperative lab values, cardiopulmonary bypass time, and all other patient outcomes besides 
allogeneic blood transfusion requirements, which was extracted from the EHR anesthesia record.  
The 4PCC exposures were identified from charge claims extracted from the Vizient database and 
validated from the EHR. A random sample of patients was independently reviewed by two study 
investigators to ensure the validity of the data collected. Any discrepancies were validated by a third 
study investigator.  
STUDY POPULATION 
Patients identified from Vizient included the following ICD-9 procedure codes: 3610, 3611, 3612, 
3613, 3614, 3615, 3616, 3619, 351, 3511, 3512, 3513, 3514, 352, 3521, 3522, 3523, 3524, 3525, 3526, 
3527, 3528, 3531, 3532, 3533, and 3732. ICD-10 procedure codes used to identify patients are found in 
the Appendix (Tables 1-3). The study sample included patients 18 years of age or older receiving open-
chest CABG, valve repair, and/or valve replacement requiring CPB. All elective, urgent, and emergent 
procedures were included in the study. Patients who received other cardiac procedures during the CABG 
or valve procedure were excluded (i.e. adult congenital cardiac operation, free wall rupture repairs, 
cardiac tumor removal etc.). Patients receiving both FFP and 4PCC intraoperatively or other factor 
concentrates other than 4PCC and FibC intraoperatively were excluded from the analysis. Patients 
documented as receiving 4PCC or FFP in the anesthesia record were included intervention groups. 
Additional exclusion criteria were patients with an unresponsive neurological state prior to procedure, 
refusal of blood products, previous aortic procedures, resuscitation prior to procedure, robot use during 
the procedure, circulatory arrest/cooling performed during procedure, pulmonary valve replacement, 
patients who did not transfer to ICU after care, patients who received factor concentrate within 24 
hours preoperatively, or received a factor concentrate within 24 hours post procedure.  
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SURGICAL PROCEDURE AND OPERATIVE MANAGEMENT 
CABG and valve procedures are conducted via a median sternotomy approach. CPB is initiated in 
a routine manner involving cannulation of the right atria, vena cava, or femoral vein to oxygenate blood 
withdrawn from the body and returning the oxygenated blood to the ascending aorta. Anticoagulants 
and antiplatelets are discontinued as appropriate prior to surgery—if the planned case is elective. 
Anticoagulation generally resumes within 24 to 48 hours post-surgery unless contraindicated to resume 
therapy (i.e. active bleeding). At our institution, intravenous heparin is administered at doses of 300 to 
400 units per kg to maintain an activated clotting time (ACT) above 450 seconds prior to the procedure.  
After the induction of anesthesia, patients receive a standard infusion of intravenous ε-aminocaproic 
acid (EACA) 10 gram bolus, followed by a 10 gram infusion during the procedure, and a 5 gram bolus at 
the end of the surgery.  When CPB is ceased, protamine sulphate is administered 1 mg per 100 units of 
heparin given during the procedure. Patients with prolonged ACT after surgery will received additional 
protamine as necessary for reversal of heparin effects. After the reversal of heparin, the anesthesiologist 
and surgery team will visually inspect the surgical field for major bleeding and/or microvascular bleeding 
to determine if blood products—RBCs, FFP, platelets, and/or factor concentrates (4PCC and/or FibC)—
are warranted as well as perform thromboelastography (TEG) if necessary. The TEG results are used to 
guide the administration of allogeneic blood products. Thus, the various modalities used to cease 
bleeding and restore hemostasis are individualized. The use and administration of factor concentrates 
and allogeneic blood products is not protocolized at our institution, and providers may use either 
allogeneic blood products or factor concentrates as per their clinical judgment. Other elements 
considered prior to administration of these treatment modalities includes prothrombin time, activated 
partial thromboplastin time, platelet count, hemoglobin, and hemodynamics. After open-chest CABG 
and valve procedures, patients are transferred to the cardiovascular intensive care unit for 
management.  
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The 4PCC product used exclusively at HMH is Kcentra (CSL Behring; Marburg, Germany), and the 
FibC product used exclusively is RiaSTAP (CSL Behring; Marburg, Germany). Kcentra was approved in 
April of 2013, and RiaSTAP was approved in January of 2009. The use of these products intraoperatively 
began in January to February 2014 for CABG and valve surgeries. Kcentra is supplied in 20 mL vials with 
approximately 500 units of Factor IX. The product is reconstituted with 2 diluents supplied with the 
medication. Kcentra is administered intraoperatively slow intravenous push following the maximum rate 
of the package insert of 210 units per minute. RiaSTAP is supplied in 50 mL vials with 900 to 1300 mg of 
lyophilized fibrinogen concentrate powder. RiaSTAP is reconstituted with 50 mL of sterile water and is 
administered slow intravenous push as recommend by the package insert.17,25 
STUDY OUTCOMES AND DEFINITIONS 
The study evaluated the effectiveness of 4PCC versus FFP used intraoperatively in CABG and valve 
surgeries requiring CPB.  The primary independent variable of interest was use 4PCC and FFP used 
intraoperatively. The other independent variables were selected based on previous published literature 
and hypothesized variables that would influence patients receiving an RBC transfusion.1-7  These 
included: 
1. Age: Age was modeled continuously by year of age. 
2. Sex: Sex was categorized for male (0) and female (1).  
3. Race: Self-reported race was categorized as white (0), black (1), Asian (2), and other (3). 
4. Surgeon: Surgeons performing the surgeries were categorized based on each individual with one 
combined variable for surgeons performing surgeries less often (surgeon other).  
5. Preoperative status (emergent/urgent or elective): Preoperative status was dichotomized as 
elective (0) or emergent/urgent (1).  
6. Combined CABG + valve procedure: Patients who received CABG plus a valve surgery were 
categorized as 1 if yes or 0 if no. 
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7. Previous open chest procedure: Patients with previous open chest procedures were categorized 
as 1 if yes or 0 if no. 
8. Body mass index (BMI): BMI was modeled as continuous variable in kg/m2. 
9. Comorbidities were based on documentation from STS and dichotomized as 1 if present and 0 if 
not. 
a. Arrhythmia: Patient was considered as having an arrhythmia if the patient had a history 
of a cardiac rhythm disturbance before the start of the operative procedure which 
includes the institution of anesthetic management. 
b. Coronary artery disease (CAD): Patient was considered as having coronary artery 
anatomy and/or disease if documented and available prior to surgery. 
c. Cerebrovascular disease (CVD): Patient was considered to have CVD if any of the 
following were present:  
i. Stroke: Stroke is an acute episode of focal or global neurological dysfunction 
caused by brain, spinal cord, or retinal vascular injury as a result of hemorrhage 
or infarction, where the neurological dysfunction lasts for greater than 24 hours. 
ii. TIA: Defined as a transient episode of focal neurological dysfunction caused by 
brain, spinal cord, or retinal ischemia, without acute infarction, where the 
neurological dysfunction resolves within 24 hours. 
iii. Noninvasive or invasive arterial imaging test demonstrating >=50% stenosis of 
any of the major extracranial or intracranial vessels to the brain. 
iv. Previous cervical or cerebral artery revascularization surgery or percutaneous 
intervention. This does not include chronic (nonvascular) neurological diseases 
or other acute neurological insults such as metabolic and anoxic ischemic 
encephalopathy. 
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d. Diabetes mellitus (DM): Patient was considered to have DM if diagnosed and/or treated 
by a healthcare provider in the past. 
e. Dyslipidemia: If the patient had a history of dyslipidemia that was diagnosed and/or 
treated by a physician. 
i. National Cholesterol Education Program (NCEP) criteria include documentation 
of the following: 
1. Total cholesterol >200 mg/dL (5.18 mmol/L); or 
2. LDL >=130 mg/dL (3.37 mmol/L); 
3. HDL <40 mg/dL (1.04 mmol/L) in men and <50 mg/dL (1.30 mmol/L) in 
women; 
4. Currently receiving antilipidemic treatment. 
f. Heart failure (HF): Patient has a history of heart failure occurring more than 2 weeks 
prior to current episode of care. 
g. Hypertension (HTN): If the patient had a current diagnosis of hypertension defined by 
any 1 of the following: 
i. History of hypertension diagnosed and treated with medication, diet, and/or 
exercise. 
ii. Prior documentation of blood pressure >140 mm Hg systolic and/or 90 mm Hg 
diastolic for patients without diabetes or chronic kidney disease, or prior 
documentation of blood pressure >130 mm Hg systolic or 80 mm Hg diastolic on 
at least 2 occasions for patients with diabetes or chronic kidney disease. 
iii. Currently undergoing pharmacological therapy for treatment of hypertension. 
h. Immunocompromised: Indicates whether the patient was immunocompromised due to 
immunosuppressive medication therapy within 30 days preceding the operative 
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procedure or existing medical condition. This includes, but is not limited to systemic 
steroid therapy, anti-rejection medications and chemotherapy. This does not include 
topical steroid applications, one time systemic therapy, inhaled steroid therapy or pre-
procedure protocol. 
i. Liver dysfunction: Patient had a history of hepatitis B, hepatitis C, cirrhosis, portal 
hypertension, esophageal varices, chronic alcohol abuse or congestive hepatopathy, 
excludes NASH in the absence of cirrhosis. 
j. History of myocardial infarction (MI): The patient had at least one documented previous 
myocardial infarction at any time prior to this surgery. 
k. Peripheral artery disease (PAD): Patient had a history of peripheral arterial disease 
(includes upper and lower extremity, renal, mesenteric, and abdominal aortic systems). 
l. Pneumonia (PNA): Patient was considered to have a history of PNA if the patient had a 
recent (within 30 days) or remote (more than 30 days) history of PNA. 
10. Anticoagulation received within 48 hours of procedure: Patients who received anticoagulation 
within 48 hours of procedure that was an intravenous and/or subcutaneous anticoagulant. 
11. Antiplatelet received within 5 days of the procedure: This variable indicated whether a patient 
received an antiplatelet within 5 days preceding surgery. 
12. Aspirin use prior to the procedure: This variable indicated whether a patient received aspirin or 
Ecotrin within 5 days preceding surgery. 
13. Categorized central venous pressure (CVP): Patient’s central venous pressure was documented 
immediately prior to incision time and categorized as 0-3 (1), 4-9 (0), 10-15 (2), and > 15 (3).   
14. Hematocrit (HCT) % prior to the procedure: HCT was modeled as a continuous variable and 
gathered within 24 hours of the procedure.  
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15. Left ventricular ejection fraction (LVEF) prior to the procedure: Last documented LVEF prior to 
induction of anesthesia. LVEF was modeled as a continuous variable.  
16. Dichotomized platelet count: The platelet count closest to the date and time prior to surgery. 
This variable was dichotomized to platelets greater than or equal to 150 (1) and less than 150 
109/L (0).   
17. Serum creatinine, mg/dL (SCr) prior to the procedure: The SCr closest to the date and time prior 
to surgery and was modeled continuously. 
18. Cell save use (units): The documented amount of cell saver units recycled intraoperatively and 
modeled continuously.  
19. Cardiopulmonary bypass (CPB) time (min): The total number of minutes that systemic return 
was diverted into the CPB circuit and returned to the systemic system. 
20. Intraoperative antithrombin III use: Documented intraoperative administration of antithrombin 
III, 1 if given and 0 if not given. 
21. Intraoperative desmopressin use: Documented intraoperative administration of desmopressin, 1 
if given and 0 if not given. 
22. Intraoperative ε-aminocaproic acid (EACA) use: Documented intraoperative administration of 
EACA, 1 if given and 0 if not given. 
Variables represented in the patient’s baseline characteristics but not included in the models were 
cancer, chronic lung disease, hemodialysis, inotrope administration prior to procedure, intraoperative 
fibrinogen concentrate, and aortic cross-clamp time (ACT). Cancer, chronic lung disease, intraoperative 
fibrinogen concentrate, and inotrope administration prior to procedure were excluded due to the small 
sample size in the study groups. SCr allowed for patients undergoing hemodialysis to be were indirectly 
controlled for in addition to mild and moderate chronic kidney disease. Finally, aortic cross-clamp time 
and surgery duration were strongly collinear to CPB and not included in the model.  
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Study outcome definitions 
Primary Effectiveness Measures  
a.  Red blood cell (RBC) transfusion intraoperatively and within 24 hours postoperatively: 
Documented intraoperative red blood cell (RBC) transfusion by the anesthesiologist and 
documented RBC transfusion by the nurse within 24 hours post-surgery. 
Secondary Effectiveness Measures 
b. Intraoperative estimated blood loss (mL) 
c. Postoperative hemoglobin (g/dL): Nadir hemoglobin documented in the EHR with 24 
hours postoperatively. 
d. Postoperative platelets (109/L): Nadir platelet count documented in the EHR with 24 
hours postoperatively. 
e. Fresh frozen plasma (FFP) use within 24 hours postoperatively: Documented FFP 
transfusion by the nurse within 24 hours post-surgery. 
f. Platelet transfusion intraoperatively and within 24 hours postoperatively: Documented 
intraoperative platelet transfusion by the anesthesiologist and documented platelet 
transfusion by the nurse within 24 hours post-surgery. 
g. Cryoprecipitate transfusion intraoperatively and within 24 hours postoperatively: 
Documented intraoperative cryoprecipitate transfusion by the anesthesiologist and 
documented cryoprecipitate transfusion by the nurse within 24 hours post-surgery. 
Primary Safety Measures 
a. Composite outcome of venous thromboembolism (VTE), pulmonary embolism (PE), 
stroke/ transient ischemic attack (TIA)), and cardiac arrest during the hospitalization. 
Secondary Safety Measures 
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a. Return to the operating room within 72 hours: Patient returned to OR within 72 hours 
post-surgery.  
b. Reoperation due to a bleed during hospitalization: Patients who were re-explored for 
mediastinal bleeding with or without tamponade either in the ICU or returned to the 
operating room. 
c. VTE during hospitalization: Patients that developed postoperative venous thrombosis or 
thromboembolic event during the hospitalization. 
d. Renal failure during hospitalization: Patient had acute renal failure or worsening renal 
function resulting in ONE OR BOTH of the following: 
a. Increase in serum creatinine level 3.0 x greater than baseline, or serum 
creatinine level ≥ 4 mg/dL (Acute rise must be at least 0.5 mg/dL) 
b. A new requirement for dialysis postoperatively 
e. Stroke or TIA during hospitalization: 
a. Patient had a postoperative stroke and the type of stroke (i.e., any confirmed 
neurological deficit of abrupt onset caused by a disturbance in blood supply to 
the brain) that did not resolve within 24 hours 
b. Patient had a postoperative Transient Ischemic Attack (TIA): Loss of neurological 
function that was abrupt in onset but with complete return of function within 
24 hours. 
f. Length of stay after surgery: Patient’s LOS after cardiac surgery.  
g. Length of stay: Patient’s total LOS including time prior to cardiac surgery. 
STATISTICAL ANALYSIS 
Multivariable logistic regression analysis was used to control for confounding variables 
hypothesized a priori that may influence patients receiving RBC transfusion. Using a backward 
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elimination function, multivariable logistic regression was performed to determine the effectiveness of 
4PCC versus FFP administered intraoperatively with the dependent variable as RBC utilization. Backward 
elimination was chosen to create a parsimonious model due to sample size in this study.26 Compared to 
other variable selection techniques in regression, backward elimination offers the advantage of 
decreasing the likelihood of omitting important negatively confounded sets of variables, because all 
variables are included in the initial model.26,27 In addition, backward elimination function performs as 
well as other stepwise/elimination functions based on simulation studies for the sample size of our 
study.27 All confounding variables found to be significant at p-value < 0.2 in a backward elimination 
function were included model.26,27 The probability of the outcome was modeled using the logarithmic 
odds as a linear function of the predictor variables. The mathematical expression of the logistic 
regression model is:  
log (𝑝/1 – 𝑝)= 𝛽0 + 𝛽1 𝑋1 + 𝛽2 𝑋2 + … + 𝛽𝑘 𝑋𝑘 
Where X1....... Xk were independent variables, and p was the probability of the occurrence of the 
outcome—RBC transfusion: no (0) or yes (1). Beta coefficients were exponentiated to provide odds 
ratios in order to interpret factors associated with patients requiring RBC transfusion.  
 Cappabianca and colleagues methodology is most similar to our methodology and study 
population. Their study found an effect size of 0.4, and we estimated our population who receives 4PCC 
or FFP to require RBC transfusion in approximately 70% of patients. Thus, we estimated 198 patents 
who be required to assess an effect size of 0.4 with 80% power.   
To validate the study findings, a sensitivity analyses on the primary endpoint was performed by 
creating a propensity score for the exposure of FFP (0) versus 4PCC (1). The propensity score was 
created by developing multivariable logistic regression with dependent variable of FFP (0) and 4PCC (1) 
that included all factors that may influence FFP and/or 4PCC administration.26,28  This model allows one 
to calculate the propensity (probability) of prescribing FFP versus 4PCC, therefore controlling for the 
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selection bias of administering either agent. All of the aforementioned variables were kept in the 
multivariable logistic regression model used to generate the propensity score to determine the 
probability of prescribing 4PCC versus FFP. The probability of prescribing FFP versus 4PCC was used as 
an independent variable as well as the actual exposure of 4PCC versus FFP in a logistic regression model 
with the dependent variable of RBC transfusion.  The propensity score was evaluated by assessing the 
overlap of probabilities between the FFP and 4PCC groups.26,28 
The safety of 4PCC compared to FFP was described by performing bivariate statistical analysis 
with a focus on thromboembolic events. Multivariable analysis was not performed on the safety 
endpoints due to the small number of safety events and the effectiveness measures being the primary 
interest. Descriptive statistics and bivariate analysis were used to compare the study samples: patients 
exposed to 4PCC, patients exposed to FFP, and patients not exposed to 4PCC or FFP (control). These 
three groups were not compared across groups but specifically assessed comparing the control to FFP, 
control to 4PCC, and 4PCC to FFP, because differences across the study groups were not of interest. 
Two-tailed bivariate analysis was performed using student’s t-test for continuous parametric data, 
Wilcoxon rank-sum test for continuous non-parametric data, and chi-square test or fisher’s exact for 
proportional data.  
A p-value of < 0.05 was accepted as indicating a statistical significance in all of the statistical 
models. The discrimination of each model was determined by calculating the C-statistic, and the 
calibration of the model was determined by performing the Hosmer-Lemeshow test. A p-value of 
greater than 0.05 for the Hosmer-Lemeshow test indicates a good fit. Statistical analyses were 
performed using SAS 9.3, SAS Institute, Cary, NC.  
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RESULTS 
STUDY POPULATION 
During the study timeframe, 690 patients (70.2%) did not receive FFP or 4PCC intraoperatively 
(control), 166 patients (16.9%) received 4PCC only, 68 patients (6.9%) received FFP only, and 58 (5.9%) 
received both 4PCC and FFP intraoperatively. After excluding patients who received both FFP and 4PCC, 
a total of 924 patients were included in the analysis of the 2,105 patients who underwent CABG and/or 
valve surgery (Figure 1). Both the administration of FFP and 4PCC were given towards end of the 
procedure when patients were taken of CPB (Time given from the end of the procedure for FFP: 1.2 ± 
1.0 hours; 4PCC: 1.0 ± 0.5 hours; p=0.109). The median dose of FFP administered intraoperatively was 2 
units (IQR: 1-2 units), and the median dose of 4PCC given intraoperatively based on the Factor IX 
component was 500 units (IQR: 500-1,000 units). 
STUDY GROUP COMPARISONS AND UNADJUSTED PATIENT OUTCOMES 
Comparison of study groups revealed that more patients in the control and FFP groups 
underwent CABG alone (Control: 56.8%; FFP: 48.5%; 4PCC: 30.1%), and less patients in the control and 
FFP groups had valve procedures alone compared to the 4PCC group (Control: 35.8%; FFP: 39.7%; 4PCC: 
58.4%).  The control group had significantly less repeat open-chests compared to the FFP and 4PCC 
groups (Control: 9.9%; FFP: 20.6%, 4PCC: 24.1%). In addition, the control group had significantly shorter 
surgeries, CPB time, aortic cross-clamp time (ACT), and required less cell saver units compared to the 
FFP and 4PCC groups, while the FFP and 4PCC groups did not differ on any of the aforementioned 
measures. Comparing the 4PCC and FFP groups, significantly less patients had dyslipidemia and liver 
dysfunction in the 4PCC group. Also, more patients exposed to 4PCC received concomitant 
desmopressin and FibC intraoperatively compared to the FFP and controls groups (Table 1).  
Bivariate analyses revealed that patients who received intraoperative FFP or 4PCC had similar 
EBL (FFP: 1382 ± 620 mL; 4PCC: 1459 ± 642 mL; p=0.427), and both had greater EBL compared to the 
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control group (Control: 1126 ± 459; FFP vs. control p=0.003; 4PCC vs. control p<0.01). The 3 groups’ 
postoperative hemoglobin (Hgb) concentrations significantly differed. The control group’s postop Hgb 
was greater than both the FFP and 4PCC groups (Control: 9.6 ± 1.6 g/dL; FFP vs. control p<0.01; 4PCC vs. 
control p<0.01), and the 4PCC group had greater postop Hgb than the FFP group (4PCC: 8.9 ± 1.4; FFP: 
7.9 ± 1.4; p<0.01). Postoperative platelet counts were similar in the control and 4PCC groups (Control: 
123 ± 44 109/L; 4PCC: 119 ± 114 109/L; p=0.255), and the FFP group had significantly lower platelets 
compared to both the control and 4PCC groups (FFP: 105 ± 96; FFP vs. control p<0.01; FFP vs. 4PCC 
p<0.01). The proportion of patients who received a RBC transfusion intraoperatively or within 24 hours 
postoperatively in control group was significantly less than the 4PCC and FFP groups (Control: 13.6%; 
Control vs. FFP p<0.01; Control vs. 4PCC p<0.01).  Patients who received 4PCC compared to FFP required 
less RBC transfusions intraoperatively and/or within 24 hours postoperatively (OR=0.43; 4PCC: 60% vs. 
FFP: 78%; p-value=0.01) as well as required less RBC units (FFP: 2.0 ± 1.7 units; 4PCC: 1.3 ± 1.9 units; 
p=0.01). Between the FFP and 4PCC groups, no difference was found in the proportion of patients 
receiving FFP within 24 hours postoperatively (FFP: 8.8%; 4PCC: 10.2%; p=0.814) or receiving 
cryoprecipitate intraoperatively or within 24 hours postoperatively (FFP: 20.6%; 4PCC: 13.9%; p=0.2).  
Many differences existed in the secondary outcomes between the control group and the FFP and 4PCC 
groups (Table 2).  
MULTIVARIABLE REGRESSION MODEL AND SENSITIVITY ANALYSIS 
For the primary endpoint, the multivariable logistic regression model comparing patients 
receiving FFP intraoperatively to 4PCC found patients receiving 4PCC had a significant reduction in the 
odds of receiving an RBC transfusion intraoperatively and/or within 24 hours postoperatively (OR: 0.28; 
95% CI: 0.13-0.62).  Table 3 includes other factors significantly associated with patients receiving an RBC 
transfusion intraoperatively and/or within 24 hours postoperatively were CVD (OR: 2.53; CI: 1.03-6.21), 
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HF (OR: 2.10; CI: 1.01-4.37), number of cell saver units transfused (OR: 1.32; CI: 1.00-1.75), and CPB time 
(OR: 1.03; CI: 1.01-1.04).  
The propensity score overlap and distributions are illustrated in Figure 2 and show a moderate 
degree of overlap based on the probability of receiving FFP versus 4PCC. When including the propensity 
score as a regressor in the logistic regression model, the sensitivity analyses revealed patients receiving 
4PCC compared to FFP also significantly reduced the odds of receiving an RBC transfusion 
intraoperatively and/or within 24 hours postoperatively (OR: 0.41; 95% CI: 0.19-0.89).  
SAFETY OUTCOMES 
No difference in the composite safety outcome was found between the study groups (Table 5). 
More patients who received 4PCC had VTE/PE (8.4%) compared to the control (2.9%; p-value=0.001) but 
not compared to the FFP group (2.9%; p-value=0.162). No patients in the FFP or 4PCC group experienced 
a PE, and 2 patients in control group had a PE. More patients returned to the OR within 72 hours 
postoperatively in the FFP group (13.9%) and 4PCC group (20.6%) compared to the control group (5.4%; 
p<0.01). No differences were found between the 3 groups in the proportion of patients who had a 
stroke or TIA in the control, developed renal failure postoperatively, or required reoperation due to a 
bleed.  The control group had a shorter total LOS and postoperative LOS compared to the FFP and 4PCC 
groups, and the FFP and 4PCC groups postoperative LOS was not significantly different (FFP: 11 (IQR 8-
13.5); 4PCC: 11 (IQR: 8-15); p=0.541). Finally, death during the hospitalization was not significantly 
different between the 3 groups.  
DISCUSSION 
This retrospective, single-institution study found 4PCC significantly reduced RBC transfusion 
requirements compared to FFP in CABG and/or valve surgery requiring CPB after controlling for other 
factors. Bivariate analysis revealed no difference in the composite safety outcome assessing 
thromboembolic events; however, patients who received 4PCC compared to the control group were 
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more likely to have a VTE/PE. These findings represent the first real-world evaluation of 4PCC compared 
to FFP in cardiac surgery in the United States. The use of factor concentrates continues to grow as 
institutions attempt to develop cost-effective and safe blood conservation strategies. At our institution, 
surgery teams may administer either 4PCC or FFP to treat excessive bleeding during surgery, which 
began at the beginning of the study timeframe. The doses of 4PCC and FFP administered in our study 
were similar based on the Factor IX component. The amount Factor IX in 2 U of FFP is approximately 500 
U, and the median dose of 4PCC patients received in our study based on the Factor IX component was 
500 U.16 Compared to other published studies, our patients received lower doses of PCC. In a 
retrospective study comparing 3PCC to FFP in CABG and valve surgery, the median 3PCC dose was 1,500 
U, and median dose of FFP was 2 U—this study did not report weight-based doses.21 Another 
retrospective study comparing 4PCC to FFP during pulmonary endarterectomy with hypothermic 
circulatory arrest used a dose of 15 U/kg of 4PCC and 15 mL/kg of FFP.22 The labeling for 4PCC 
recommends a dosing range of 25 to 50 U/kg for the reversal of acute major bleeding based on INR.17 
The upper end of this dosing range has resulted in fatal thrombus formation reported in cardiac surgery, 
and why 4PCC contains a Black Box warning for patients with thromboembolic disease.17,29 With PCC 
becoming more widely adopted in cardiac surgery, the optimal dosing strategy for patients remains 
unknown and requires further investigation to ensure effective and safe doses are selected. 
Despite our patients receiving lower doses of 4PCC and FFP, we found a similar effect size 
regarding the effectiveness of 4PCC reducing RBC transfusions as Cappabianca and colleagues who 
utilized propensity adjusted (OR: 0.50 CI: 0.31-0.80) and matching techniques (OR: 0.38) for their 
analysis.21 Our primary endpoint included intraoperative as well as 24 hour postoperative RBC 
transfusion, where Cappabianca did not include intraoperative RBC transfusion in their secondary 
endpoint. Our study team determined that the inclusion of intraoperative RBC transfusion to be a more 
conservative approach for our analysis, because FFP and/or 4PCC are typically given first to mitigate 
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blood loss and more than one dose of FFP and/or 4PCC could be given during the procedure. The 
majority of doses of FFP and 4PCC occurred immediately after patients were taken off CPB, then RBC 
transfusions are administered based on the patient status intraoperatively as well as postoperatively. 
Excluding RBC transfusions administered intraoperatively, patients who received 4PCC compared to FFP 
also had significantly less RBC transfusions 24 hours postoperatively in an unadjusted analysis (FFP: 
51.5%; 4PCC: 15.7%; p-value<0.01). In a small randomized study, Demeyere and colleagues administered 
4PCC or FFP before surgery to reverse an INR > 2 and immediately after patients were taken off CPB.20 
This study found the administration of 4PCC caused faster normalization of INR as well as patients 
requiring less blood transfusions.20 
In our unadjusted analysis, our study found more patients developed VTE compared to patients 
who did not receive FFP or 4PCC, and no differences were observed in postoperative renal failure in the 
3 study groups. However, a greater proportion of patients who received 4PCC developed renal failure 
compared to the FFP and control groups in our study. Cappabianca and colleagues found a significant 
association with the administration of 3PCC administration and AKI and RRT after propensity adjustment 
but not after propensity score matching.21 No thromboembolic complications or renal dysfunction was 
noted postoperatively in the FFP or 4PCC groups by Demeyere and colleagues.20  
 Other published literature regarding PCC use in cardiac surgery used different methodologies 
and study populations, which found varying results. Arnekian performed a retrospective observational 
study with 3 treatment groups: 4PCC, FFP, and 3PCC plus FFP for treatment of active bleeding post-
cardiac surgery.19 The 4PCC only group was found to significantly reduce blood loss based on chest-tube 
output compared to the FFP group. Only 1 thromboembolic event was noted in the FFP group, and 
postoperative renal function was not evaluated. Also, this study did not perform any multivariable 
analysis to control for confounding variables and selection bias.19 In a quasi-experimental study by 
Görlinger and colleagues, 4PCC and FibC were administered first-line for the treatment of refractory 
Colavecchia 64 
 
bleeding using a ROTEM guided algorithm.23 This algorithmic based protocol significantly reduced 
allogeneic blood product transfusions after this strategy was implemented, and no significant 
differences were noted in thromboembolic complications before and after the adoption of the 
algorithm.23 Ortmann and colleagues assessed the effectiveness and safety of 4PCC compared to FFP 
during pulmonary endarterectomy with hypothermic circulatory arrest.22 This study found no difference 
in blood transfusion requirements in the 4PCC versus FFP groups. More patients developed 
postoperative renal dysfunction in the 4PCC group, but this finding was not significantly different 
compared to the FFP group after propensity score adjustment.22 
None of the aforementioned studies found PCC exposure was associated with an increase in 
blood product utilization compared to FFP, and several studies found a significant reduction in blood 
transfusion requirements in cardiac surgery.20,21,23 These findings are also consistent with in vitro and ex 
vivo studies comparing allogeneic blood products to synthetic factor concentrates as well as the time it 
takes to prepare and administer PCC products.16-18 In an ex vivo study of patients receiving CPB for 
cardiac surgery, FibC plus recombinant Factor VIIa and FibC plus 3PCC were found to be the most 
efficacious to reverse coagulopathy after stopping CPB compared to FFP and FFP in combination with 
other products in patient blood samples.18 The patients included in the ex vivo analysis did not have 
excessive bleeding. The effectiveness of PCC compared to FFP may also be attributed to the ability to 
administer PCC more quickly, potentially faster availability of the product depending on institutional 
workflow, and increased potency of PCC products.   
STRENGTHS AND LIMITATIONS 
This study contains both strengths and weaknesses that should be considered before 
extrapolating the results to other institutions. First, this study utilized the STS database for several safety 
outcomes, which researchers frequently use to evaluate cardiac surgery quality and safety. Two 
different multivariable analyses techniques were used to control for confounding variables and selection 
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bias that yielded similar results. The study groups included patients throughout the study timeframe and 
eliminates historical control bias encountered in quasi-experimental designs and retrospective 
observational studies using a historical control group. Finally, the findings of this study area based on 
the real-world data in the United States to evaluate 4PCC and FFP in cardiac surgery.  
 Like all retrospective studies, our study runs the risk of bias with any measurable or 
immeasurable variables unaccounted for in the analysis. These unaccounted variables may have 
influenced the selection of FFP and/or 4PCC, which introduces potential selection bias. In the 
multivariable analysis, FibC was excluded from the model, because only one exposure occurred in the 
FFP group. Thus, the effect of FibC could not be isolated from 4PCC in the multivariable analysis, where 
20% of patients received FibC. The results also reflect the practices of a single institution with a limited 
sample size receiving FFP and 4PCC included in the study. The study excluded many patients to create a 
homogenous cohort, which needs to be considered before extrapolating to different surgery types and 
patient populations.  
CONCLUSIONS 
In patients undergoing isolated CABG and/or valve surgery, this single-center retrospective 
study found intraoperative administration of 4PCC compared to FFP reduced allogeneic RBC transfusions 
intraoperatively and within 24 hours postoperatively. Also, the administration of 4PCC should be 
carefully considered in patients with thromboembolic disease due to the risk of thrombosis. A large, 
multicenter, randomized study would provide valuable insight regarding the efficacy and safety of 
prothrombin complex concentrates in cardiac surgery. 
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CHAPTER IV: 
CONCLUSIONS AND IMPLICATIONS 
The use of PCCs for the treatment of bleeding intraoperatively and postoperatively continues to 
increase globally, and the adoption of these products is multifactorial. Despite many technological and 
surgical advancements, patients who require life-saving procedures such as CABG and valve surgery will 
inevitably bleed due to the invasiveness of these procedures. Patients with excessive bleeding that 
receive blood transfusions have many complications and worse outcomes compared to patients who do 
not. Thus, any strategy that mitigates excessive blood loss and transfusion deserves attention, as PCCs 
have gained in the surgical community. Multiple studies have proven PCCs’ favorable profile in vivo and 
ex vivo to reverse hypercoagulability. In addition, one small randomized study and several observational 
studies found PCC use to be safe and effective in specific cardiac procedures and patient populations. 
This supporting evidence has led PCCs to be recognized as a therapeutic option in clinical practice 
guidelines for the treatment excessive bleeding in surgery.  
In our study, we found an increasing use of 4PCC in cardiac surgery with many factors predictive 
of 4PCC use intraoperatively such as patients with HTN. In some circumstances, providers show a 
preference for using FFP compared to 4PCC such as in patients with liver dysfunction. Knowing where 
providers choose to administer 4PCC versus FFP will help optimize the effective and safe use of these 
products and improve future prescribing patterns.  
Finally, this study found 4PCC compared to FFP to reduce RBC transfusion requirements in 
patients receiving isolated CABG and/or valve surgery requiring CPB, and 4PCC may increase the risk of 
VTE compared to patients not receiving 4PCC or FFP. Ultimately, a well-designed, randomized clinical 
trial needs to be performed to confirm the clinical utility of PCC use in cardiac surgery for the treatment 
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of excessive bleeding. Currently, a randomized clinical trial is assessing PCC versus FFP in cardiac surgery, 
which is expected to finish in 2018.    
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TABLES 
CHAPTER II TABLES 
Table 1. Comparison of Patient Baseline Characteristics 
Variable Control/None 
(n=690) 
FFP  
(n=68) 
4PCC 
(n=166) 
 FFP v None 
p-value 
4PCC v None 
p-value 
FFP v 4PCC 
p-value 
Age, mean ± sd 65.5 ± 11.4 65.9 ± 10.9 67.1 ± 12.5 0.7954 0.1011 0.4647 
Male, n (%) 208 (30.1) 45 (66.2) 111 (66.9) 0.5295 0.4538 0.9189 
Race       
    White, n (%) 513 (74.4) 42 (61.8) 114 (68.7) 
0.1241 0.2727 0.6048 
    Black, n (%) 49 (7.1) 7 (10.3) 17 (10.2) 
    Asian, n (%) 24 (3.5) 3 (4.4) 4 (2.4) 
    Other, n (%) 104 (15.1) 16 (23.5) 31 (18.7) 
BMI (kg/m2), mean ± sd 29.5 ± 5.7 28.8 ± 12.5 28.0 ± 5.8 0.6643 0.0024 0.5976 
Surgeon 1, n (%) 264 (38.3) 29 (42.7) 90 (54.2) 
0.428 0.005 0.3095 
Surgeon 2, n (%) 138 (20.0) 9 (13.2) 15 (9.0) 
Surgeon 3, n (%) 113 (16.4) 8 (11.8) 23 (13.9) 
Surgeon 4, n (%)  60 (8.7) 9 (13.2) 11 (6.6) 
Surgeon 5, n (%) 55 (8.0) 8 (11.8) 12 (7.2) 
Surgeon 6, n (%)  47 (6.8) 3 (4.4) 12 (7.2) 
Surgeon Other, n (%)  13 (1.9) 2 (2.9) 3 (1.8) 
Surgery type       
    CABG, n (%) 392 (56.8) 33 (48.5) 50 (30.1) 
0.2808 <0.0001 0.0202     Valve, n (%) 247 (35.8) 27 (39.7) 97 (58.4) 
    CABG + valve, n (%) 51 (7.4) 8 (11.8) 19 (11.5) 
Graft count       
    0, n (%) 247 (35.8) 27 (39.7) 97 (58.4) 
0.2726 <0.0001 0.0437 
    1, n (%) 44 (6.4) 1 (1.5) 7 (4.2) 
    2, n (%) 95 (13.8) 13 (19.1) 18 (10.8) 
    3, n (%) 233 (33.8) 23 (33.8) 37 (22.3) 
    ≥ 4, n (%) 71 (10.3) 4 (5.9) 7 (4.2) 
Open chest repeat, n (%) 68 (9.9) 14 (20.6) 40 (24.1) 0.0066 <0.0001 0.5631 
Preop status (non-elective), n 
(%) 
228 (33.0) 35 (51.5) 76 (45.8) 0.0023 0.0021 0.4289 
Comorbidities       
Arrhythmia, n (%) 174 (25.2) 17 (25.0) 52 (31.3) 0.9686 0.109 0.3353 
Cancer (within 5 years),  
n (%) 
37 (5.4) 1 (1.5) 8 (4.9) 0.2422 0.7876 0.2904 
Cerebrovascular disease,  
n (%) 
130 (18.8) 21 (30.9) 33 (19.9) 0.0177 0.7595 0.0697 
Chronic lung disease, n (%)       
        None 535 (77.5) 56 (82.4) 121 (72.9) 
0.4113 --- --- 
        Mild 79 (11.5) 5 (7.4) 23 (13.9) 
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        Moderate 32 (4.6) 2 (2.9) 10 (6.0) 
        Severe 24 (3.5) 5 (7.4) 5 (3.0) 
        Unknown severity 16 (2.3) 0 (0) 5 (3.0) 
        Unknown 4 (0.6) 0 (0) 2 (1.2) 
Coronary artery disease,  
n (%) 
85 (12.4) 4 (5.9) 11 (6.6) 0.1646 0.0351 1 
DM, n (%) 270 (39.1) 30 (44.1) 57 (34.3) 0.4223 0.2538 0.1599 
Dyslipidemia, n (%) 555 (80.4) 56 (82.4) 111 (66.9) 0.7027 0.0002 0.0173 
Heart failure, n (%) 191 (27.8) 27 (39.7) 64 (38.6) 0.0381 0.0064 0.8697 
Hemodialysis, n (%) 35 (5.1) 8 (11.8) 14 (8.4) 0.0228 0.0942 0.428 
Hypertension, n (%) 615 (89.1) 56 (82.4) 143 (86.1) 0.0944 0.278 0.4603 
Immunocompromised, n (%) 43 (6.2) 7 (10.3) 14 (8.4) 0.1979 0.307 0.6512 
Liver disease, n (%) 52 (7.6) 14 (20.6) 16 (9.6) 0.0003 0.3713 0.0229 
Myocardial infarction, n (%) 214 (31.1) 25 (36.8) 45 (27.1) 0.3342 0.32 0.143 
Peripheral arterial disease,  
n (%) 
80 (11.6) 11 (16.2) 24 (14.5) 0.2673 0.3106 0.7379 
Pneumonia, n (%) 51 (7.4) 4 (5.9) 16 (9.6) 0.8089 0.347 0.446 
Sleep Apnea, n (%) 94 (13.6) 3 (4.4) 16 (9.6) 0.0342 0.1666 0.2907 
Medications prior to surgery       
Anticoag. within 48 hours,  
n (%) 
135 (19.6) 18 (26.5) 50 (30.1) 0.1759 0.003 0.5766 
Antiplatelet within 5 days,  
n (%) 
64 (9.3) 4 (5.9) 9 (5.4) 0.5034 0.1105 1 
Aspirin, n (%) 276 (40.2) 27 (39.7) 68 (41.2) 0.94 0.8073 0.884 
Inotrope, n (%) 4 (0.6) 2 (2.9) 4 (2.4) 0.0939 0.05 1 
Preoperative labs       
CVP       
    0-3 282 (41.1) 29 (43.3) 61 (37.0) 
0.487 0.007 0.625 
    4-9 318 (46.3) 26 (38.8) 66 (40.0) 
    10-15 64 (9.3) 8 (11.9) 30 (18.2) 
    > 15 23 (3.4) 4 (6.0) 8 (4.9) 
Hematocrit (%), mean ± sd 39 ± 5.6 37.4 ± 7.0 36.1 ± 6.3 0.0666 <0.0001 0.1896 
INR, mean ± sd 1.07 ± 0.13 1.13 ± 0.14 1.18 ± 0.21 0.0004 <0.0001 0.0683 
LVEF (%), mean ± sd 56.0 ± 11.7 53.5 ± 14.0 54.6 ± 13.1 0.1581 0.2089 0.5679 
Platelet (109/L), mean ± sd 215 ± 65 197 ± 83 197 ± 64 0.0852 0.0018 0.9644 
SCr (mg/dL), mean ± sd 1.3 ± 1.3 1.7 ± 1.2 1.5 ± 1.6 0.1483 0.0918 0.5872 
Intraoperative measures       
FFP dose (mL/kg)/ 4PCC dose 
(unit/kg), mean ± sd 
--- 5.9 ± 3.4 9.0 ± 5.8 --- --- --- 
FFP dose units/4PCC dose 
units, median (Q1,Q3) 
--- 2 (1,2) 
500 
(500,1000) 
--- --- --- 
4PCC/FFP time given to 
surgery end (hr), mean ± sd 
--- 1.2 ± 1.0 1.0 ± 0.5 --- --- 0.109 
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Surgery duration (hr),  
mean ± sd 
3.9 ± 1.1 4.6 ± 1.4 4.4 ± 1.2 <0.0001 <0.0001 0.1933 
Cell saver use (units),  
mean ± sd 
2.0 ± 1.1 2.4 ± 1.2 2.8 ± 1.5 0.0032 <0.0001 0.055 
CPB time (min), mean ± sd 
86 ± 35 97.9 ± 34.3 
100.2 ± 
47.1 
0.0074 <0.0001 0.7123 
ACT time (min), mean ± sd 67.8 ± 28.4 79.0 ± 29.7 78.7 ± 33.3 0.0024 <0.0001 0.9422 
Intraoperative medications       
Antithrombin III, n (%) 35 (5.1) 3 (4.4) 12 (7.2) 1 0.2735 0.563 
Desmopressin, n (%) 152 (22.0) 24 (35.3) 84 (50.0) 0.0134 <0.0001 0.0403 
EACA, n (%) 659 (95.5) 65 (95.6) 155 (93.4) 1 0.2532 0.7625 
FibC, n (%) 2 (0.3) 1 (1.5) 33 (19.9) 0.246 <0.0001 <0.0001 
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Table 2. Factors Associated with Use of 4PCC excluding patients who received FFP 
intraoperatively 
Variable Odds ratio 95% CI Interval p-value 
Predisposing factors     
Age 1.026 1.005 1.048 0.0146 
Female (ref male) 0.608 0.365 1.013 0.056 
Race (ref white)     
    Black 1.126 0.488 2.598 0.8509 
    Asian 1.385 0.401 4.784 0.7675 
    Other 1.339 0.735 2.438 0.6962 
Enabling factors     
Emergent procedure 1.445 0.824 2.536 0.199 
Surgeon (ref 1)     
    Surgeon 2 0.32 0.144 0.711 0.5425 
    Surgeon 3 0.296 0.132 0.663 0.3521 
    Surgeon 4 0.232 0.086 0.623 0.1705 
    Surgeon 5 0.42 0.173 1.02 0.8837 
    Surgeon 6 0.546 0.203 1.47 0.4775 
    Surgeon Other 0.318 0.064 1.581 0.7355 
Need factors     
BMI 0.937 0.897 0.979 0.0037 
CABG + Valve 0.729 0.352 1.51 0.3953 
Repeat chest 1.716 0.923 3.192 0.0881 
Arrhythmia 0.552 0.32 0.952 0.0325 
CAD 0.808 0.358 1.823 0.608 
CVD 0.913 0.523 1.594 0.75 
DM 0.671 0.405 1.11 0.1204 
Dyslipidemia 0.486 0.277 0.854 0.012 
HF 1.134 0.688 1.869 0.6225 
HTN 1.37 0.66 2.844 0.3985 
Immunocompromised 1.316 0.573 3.025 0.5171 
Liver dysfunction 0.543 0.233 1.266 0.1575 
MI 0.864 0.5 1.494 0.6011 
PAD 1.557 0.802 3.024 0.1912 
PNA 0.651 0.29 1.461 0.298 
Anticoag. within 48 
hours 
1.009 0.54 1.885 0.9768 
Anti-plt within 5 days 1.072 0.427 2.691 0.8828 
Aspirin 1.414 0.829 2.411 0.204 
CVP (ref 4-9)     
    CVP: 0-3 1.192 0.734 1.938 0.6599 
    CVP: 10-15 1.682 0.805 3.513 0.3669 
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    CVP: > 15 1.441 0.491 4.232 0.805 
HCT preop (%) 0.914 0.873 0.957 0.0001 
INR preop 16.109 4.042 64.208 <0.0001 
LVEF (%) 0.994 0.976 1.013 0.5513 
Plt preop (ref plt < 150, 
109/L) 
0.548 0.315 0.953 0.0333 
SCr preop (mg/dL) 0.918 0.772 1.091 0.3315 
Cell saver use (unit) 1.816 1.49 2.214 <0.0001 
CPB time (min) 1.016 1.008 1.024 <0.0001 
Antithrombin III 
intraop 
0.901 0.374 2.169 0.8159 
EACA intraop 0.341 0.144 0.807 0.0143 
Desmopressin intraop 3.507 2.209 5.566 <0.0001 
C-statistic=0.851; Hosmer-Lemeshow=0.0659 
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Table 3. Factors Associated with Use of FFP excluding patients who received 4PCC 
intraoperatively 
Variable Odds ratio 95% CI Interval p-value 
Predisposing Factors     
Age 1.012 0.985 1.04 0.3738 
Female (ref male) 1.15 0.59 2.24 0.6818 
Race (ref white)     
    Black 0.804 0.268 2.413 0.3884 
    Asian 1.319 0.321 5.415 0.823 
    Other 1.759 0.871 3.556 0.2107 
Enabling Factors     
Emergent procedure 2.234 1.115 4.477 0.0235 
Surgeon (ref 1)     
    Surgeon 2 0.504 0.197 1.291 0.4875 
    Surgeon 3 0.538 0.188 1.538 0.608 
    Surgeon 4 0.868 0.305 2.466 0.533 
    Surgeon 5 0.629 0.201 1.967 0.8924 
    Surgeon 6 0.587 0.145 2.384 0.8292 
    Surgeon Other 0.699 0.124 3.935 0.9556 
Need Factors     
BMI 0.999 0.951 1.05 0.9773 
CABG + Valve 1.414 0.528 3.789 0.4907 
Repeat chest 1.716 0.787 3.742 0.1748 
Arrhythmia 0.754 0.367 1.55 0.4428 
CAD 0.546 0.176 1.691 0.2939 
CVD 2.123 1.106 4.076 0.0236 
DM 1.22 0.636 2.339 0.5496 
Dyslipidemia 1.323 0.562 3.114 0.521 
HF 1.292 0.679 2.46 0.4346 
HTN 0.458 0.188 1.118 0.0863 
Immunocompromised 1.051 0.353 3.127 0.9286 
Liver dysfunction 2.004 0.855 4.699 0.1099 
MI 1.157 0.596 2.247 0.6666 
PAD 1.295 0.57 2.938 0.5369 
PNA 0.609 0.235 1.582 0.3084 
Anticoag. within 48 
hours 
0.899 0.392 2.061 0.8011 
Anti-plt within 5 days 0.669 0.203 2.201 0.5085 
Aspirin 1.09 0.535 2.221 0.8124 
CVP (ref 4-9)     
    CVP: 0-3 0.768 0.405 1.457 0.4488 
    CVP: 10-15 0.665 0.239 1.851 0.3761 
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    CVP: > 15 1.537 0.408 5.788 0.3323 
HCT preop (%) 0.99 0.932 1.052 0.7479 
INR preop 5.309 0.716 39.381 0.1025 
LVEF (%) 0.991 0.967 1.015 0.4664 
Plt preop (ref plt < 150, 
109/L) 
0.684 0.322 1.453 0.3229 
SCr preop (mg/dL) 1.145 0.961 1.365 0.1304 
Cell saver use (unit) 1.415 1.1 1.819 0.0068 
CPB time (min) 1.005 0.995 1.016 0.3278 
Antithrombin III 
intraop 
0.627 0.159 2.465 0.5036 
EACA intraop 0.702 0.187 2.638 0.6007 
Desmopressin intraop 1.675 0.883 3.177 0.114 
C-statistic= 0.777; Hosmer-Lemeshow=0.4826 
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Table 4. Comparison of factors predicting the use of 4PCC versus FFP intraoperatively 
Variable Odds Ratio 95% CI Interval p-value 
Predisposing Factors     
Female (ref male) 0.575 0.275 1.203 0.1416 
Enabling Factors     
Emergent procedure 0.502 0.248 1.016 0.0555 
Need Factors     
BMI 0.97 0.936 1.006 0.1055 
CVD 0.525 0.251 1.101 0.088 
Dyslipidemia 0.428 0.185 0.99 0.0474 
HTN 2.584 1.013 6.596 0.047 
Immunocompromised 2.466 0.678 8.964 0.1706 
Liver dysfunction 0.163 0.056 0.475 0.0009 
HCT preop (%) 0.919 0.864 0.978 0.0074 
INR preop 5.393 0.686 42.4 0.1092 
SCr preop (mg/dL) 0.852 0.703 1.032 0.1022 
Cell saver use (unit) 1.316 1.007 1.721 0.0441 
CPB time (min) 1.005 0.998 1.013 0.1528 
Desmopressin intraop 2.264 1.143 4.481 0.019 
C-statistic= 0.753; Hosmer-Lemeshow=0.8418 
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CHAPTER III TABLES 
Table 1. Comparison of Patient Baseline Characteristics 
Variable Control/None 
(n=690) 
FFP  
(n=68) 
4PCC 
(n=166) 
 FFP v None 
p-value 
4PCC v None 
p-value 
FFP v 4PCC 
p-value 
Age, mean ± sd 65.5 ± 11.4 65.9 ± 10.9 67.1 ± 12.5 0.7954 0.1011 0.4647 
Male, n (%) 208 (30.1) 45 (66.2) 111 (66.9) 0.5295 0.4538 0.9189 
Race       
    White, n (%) 513 (74.4) 42 (61.8) 114 (68.7) 
0.1241 0.2727 0.6048 
    Black, n (%) 49 (7.1) 7 (10.3) 17 (10.2) 
    Asian, n (%) 24 (3.5) 3 (4.4) 4 (2.4) 
    Other, n (%) 104 (15.1) 16 (23.5) 31 (18.7) 
BMI (kg/m2), mean ± sd 29.5 ± 5.7 28.8 ± 12.5 28.0 ± 5.8 0.6643 0.0024 0.5976 
Surgeon 1, n (%) 264 (38.3) 29 (42.7) 90 (54.2) 
0.428 0.005 0.3095 
Surgeon 2, n (%) 138 (20.0) 9 (13.2) 15 (9.0) 
Surgeon 3, n (%) 113 (16.4) 8 (11.8) 23 (13.9) 
Surgeon 4, n (%)  60 (8.7) 9 (13.2) 11 (6.6) 
Surgeon 5, n (%) 55 (8.0) 8 (11.8) 12 (7.2) 
Surgeon 6, n (%)  47 (6.8) 3 (4.4) 12 (7.2) 
Surgeon Other, n (%)  13 (1.9) 2 (2.9) 3 (1.8) 
Surgery type       
    CABG, n (%) 392 (56.8) 33 (48.5) 50 (30.1) 
0.2808 <0.0001 0.0202     Valve, n (%) 247 (35.8) 27 (39.7) 97 (58.4) 
    CABG + valve, n (%) 51 (7.4) 8 (11.8) 19 (11.5) 
Graft count       
    0, n (%) 247 (35.8) 27 (39.7) 97 (58.4) 
0.2726 <0.0001 0.0437 
    1, n (%) 44 (6.4) 1 (1.5) 7 (4.2) 
    2, n (%) 95 (13.8) 13 (19.1) 18 (10.8) 
    3, n (%) 233 (33.8) 23 (33.8) 37 (22.3) 
    ≥ 4, n (%) 71 (10.3) 4 (5.9) 7 (4.2) 
Open chest repeat, n (%) 68 (9.9) 14 (20.6) 40 (24.1) 0.0066 <0.0001 0.5631 
Preop status (non-elective), n 
(%) 
228 (33.0) 35 (51.5) 76 (45.8) 0.0023 0.0021 0.4289 
Comorbidities       
Arrhythmia, n (%) 174 (25.2) 17 (25.0) 52 (31.3) 0.9686 0.109 0.3353 
Cancer (within 5 years),  
n (%) 
37 (5.4) 1 (1.5) 8 (4.9) 0.2422 0.7876 0.2904 
Cerebrovascular disease,  
n (%) 
130 (18.8) 21 (30.9) 33 (19.9) 0.0177 0.7595 0.0697 
Chronic lung disease, n (%)       
        None 535 (77.5) 56 (82.4) 121 (72.9) 
0.4113 --- --- 
        Mild 79 (11.5) 5 (7.4) 23 (13.9) 
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        Moderate 32 (4.6) 2 (2.9) 10 (6.0) 
        Severe 24 (3.5) 5 (7.4) 5 (3.0) 
        Unknown severity 16 (2.3) 0 (0) 5 (3.0) 
        Unknown 4 (0.6) 0 (0) 2 (1.2) 
Coronary artery disease,  
n (%) 
85 (12.4) 4 (5.9) 11 (6.6) 0.1646 0.0351 1 
DM, n (%) 270 (39.1) 30 (44.1) 57 (34.3) 0.4223 0.2538 0.1599 
Dyslipidemia, n (%) 555 (80.4) 56 (82.4) 111 (66.9) 0.7027 0.0002 0.0173 
Heart failure, n (%) 191 (27.8) 27 (39.7) 64 (38.6) 0.0381 0.0064 0.8697 
Hemodialysis, n (%) 35 (5.1) 8 (11.8) 14 (8.4) 0.0228 0.0942 0.428 
Hypertension, n (%) 615 (89.1) 56 (82.4) 143 (86.1) 0.0944 0.278 0.4603 
Immunocompromised, n (%) 43 (6.2) 7 (10.3) 14 (8.4) 0.1979 0.307 0.6512 
Liver disease, n (%) 52 (7.6) 14 (20.6) 16 (9.6) 0.0003 0.3713 0.0229 
Myocardial infarction, n (%) 214 (31.1) 25 (36.8) 45 (27.1) 0.3342 0.32 0.143 
Peripheral arterial disease,  
n (%) 
80 (11.6) 11 (16.2) 24 (14.5) 0.2673 0.3106 0.7379 
Pneumonia, n (%) 51 (7.4) 4 (5.9) 16 (9.6) 0.8089 0.347 0.446 
Sleep Apnea, n (%) 94 (13.6) 3 (4.4) 16 (9.6) 0.0342 0.1666 0.2907 
Medications prior to surgery       
Anticoag. within 48 hours,  
n (%) 
135 (19.6) 18 (26.5) 50 (30.1) 0.1759 0.003 0.5766 
Antiplatelet within 5 days,  
n (%) 
64 (9.3) 4 (5.9) 9 (5.4) 0.5034 0.1105 1 
Aspirin, n (%) 276 (40.2) 27 (39.7) 68 (41.2) 0.94 0.8073 0.884 
Inotrope, n (%) 4 (0.6) 2 (2.9) 4 (2.4) 0.0939 0.05 1 
Preoperative labs       
CVP       
    0-3 282 (41.1) 29 (43.3) 61 (37.0) 
0.487 0.007 0.625 
    4-9 318 (46.3) 26 (38.8) 66 (40.0) 
    10-15 64 (9.3) 8 (11.9) 30 (18.2) 
    > 15 23 (3.4) 4 (6.0) 8 (4.9) 
Hematocrit (%), mean ± sd 39 ± 5.6 37.4 ± 7.0 36.1 ± 6.3 0.0666 <0.0001 0.1896 
INR, mean ± sd 1.07 ± 0.13 1.13 ± 0.14 1.18 ± 0.21 0.0004 <0.0001 0.0683 
LVEF (%), mean ± sd 56.0 ± 11.7 53.5 ± 14.0 54.6 ± 13.1 0.1581 0.2089 0.5679 
Platelet (109/L), mean ± sd 215 ± 65 197 ± 83 197 ± 64 0.0852 0.0018 0.9644 
SCr (mg/dL), mean ± sd 1.3 ± 1.3 1.7 ± 1.2 1.5 ± 1.6 0.1483 0.0918 0.5872 
Intraoperative measures       
FFP dose (mL/kg)/ 4PCC dose 
(unit/kg), mean ± sd 
--- 5.9 ± 3.4 9.0 ± 5.8 --- --- --- 
FFP dose units/4PCC dose 
units, median (Q1,Q3) 
--- 2 (1,2) 
500 
(500,1000) 
--- --- --- 
4PCC/FFP time given to 
surgery end (hr), mean ± sd 
--- 1.2 ± 1.0 1.0 ± 0.5 --- --- 0.109 
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Surgery duration (hr),  
mean ± sd 
3.9 ± 1.1 4.6 ± 1.4 4.4 ± 1.2 <0.0001 <0.0001 0.1933 
Cell saver use (units),  
mean ± sd 
2.0 ± 1.1 2.4 ± 1.2 2.8 ± 1.5 0.0032 <0.0001 0.055 
CPB time (min), mean ± sd 
86 ± 35 97.9 ± 34.3 
100.2 ± 
47.1 
0.0074 <0.0001 0.7123 
ACT time (min), mean ± sd 67.8 ± 28.4 79.0 ± 29.7 78.7 ± 33.3 0.0024 <0.0001 0.9422 
Intraoperative medications       
Antithrombin III, n (%) 35 (5.1) 3 (4.4) 12 (7.2) 1 0.2735 0.563 
Desmopressin, n (%) 152 (22.0) 24 (35.3) 84 (50.0) 0.0134 <0.0001 0.0403 
EACA, n (%) 659 (95.5) 65 (95.6) 155 (93.4) 1 0.2532 0.7625 
FibC, n (%) 2 (0.3) 1 (1.5) 33 (19.9) 0.246 <0.0001 <0.0001 
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Table 2. Unadjusted Analysis of Patient Effectiveness Outcomes for Exposure Groups  
Outcomes 
Control 
(n=690) 
FFP 
(n=68) 
4PCC 
(n=166) 
FFP v None 
p-value 
4PCC v None 
p-value 
FFP v 4PCC 
p-value 
Intraoperative EBL 
(mL), mean ± sd 
1126 ± 459 1382 ± 620 1459 ± 642 0.0025 <0.0001 0.4268 
Postop Hgb (g/dL), 
mean ± sd 
9.6 ± 1.6 7.9 ± 1.4 8.9 ± 1.4 <0.0001 <0.0001 <0.0001 
Post-operative Plt, 
109/L 
123 ± 44 105 ± 96 119 ± 114 0.0011 0.2552 0.0071 
Transfusion 
requirements 
      
    RBC, n (%) 94 (13.6) 53 (77.9) 100 (60.2) <0.0001 <0.0001 0.0098 
    RBC (units),  
    mean ± sd 
0.2 ± 0.6 2.0 ± 1.7 1.3 ± 1.9 <0.0001 <0.0001 0.0104 
    RBC 24 hr postop, 
    n (%) 
53 (7.7) 35 (51.5) 26 (15.7) <0.0001 0.0024 <0.0001 
    FFP 24 hr postop, 
    n (%) 
32 (4.6) 6 (8.8) 17 (10.2) 0.2232 0.0092 0.8141 
    Plt, n (%) 6 (0.9) 20 (29.4) 14 (8.4) <0.0001 <0.0001 <0.0001 
    Cryoprecipitate,  
    n (%) 
37 (5.4) 14 (20.6) 23 (13.9) <0.0001 0.0001 0.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Colavecchia 83 
 
Table 3. Effect of 4PCC versus FFP on RBC Transfusion in Cardiac Surgery: Logistic Regression 
Variable Odds ratio 95% CI Interval p-value 
4PCC (ref FFP) 0.281 0.127 0.621 0.0017 
BMI 0.954 0.902 1.01 0.105 
Surgeon (ref 1)     
    Surgeon 2 0.2 0.059 0.68 0.7201 
    Surgeon 3 0.149 0.043 0.513 0.3152 
    Surgeon 4 0.289 0.075 1.112 0.7551 
    Surgeon 5 0.177 0.039 0.808 0.6194 
    Surgeon 6 0.37 0.098 1.391 0.4791 
    Surgeon Other 0.087 0.006 1.237 0.354 
CABG + Valve 3.708 0.922 14.915 0.065 
CVD 2.533 1.034 6.206 0.0422 
DM 1.942 0.887 4.251 0.0971 
HF 2.097 1.006 4.371 0.0481 
HCT preop (%) 0.957 0.904 1.012 0.1252 
LVEF (%) 0.981 0.955 1.008 0.1603 
Plt preop (ref plt < 150, 
109/L) 
0.524 0.224 1.228 0.1371 
Cell saver use (unit) 1.323 1.002 1.747 0.0484 
CPB time (min) 1.025 1.013 1.037 <0.0001 
Antithrombin III intraop 0.33 0.085 1.279 0.1087 
Backward elimination regression of p-value < 0.2 
C-statistic=0.803; Hosmer-Lemeshow=0.594 
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Table 4. Effect of 4PCC versus FFP in the proportion of patients requiring RBC transfusion 
during and post-cardiac surgery: Sensitivity Analysis 
Variable Odds ratio 95% CI Interval p-value 
4PCC (ref FFP) 0.41 0.19 0.89 0.023 
Propensity score 1.09 0.25 4.73 0.907 
C-statistic=0.623; Hosmer-Lemeshow=0.549 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Colavecchia 85 
 
Table 5. Unadjusted Analysis of Patient Safety Outcomes for Exposure Groups 
Safety Outcomes 
Control 
(n=690) 
FFP 
(n=68) 
4PCC 
(n=166) 
FFP v None 
p-value 
4PCC v None 
p-value 
FFP v 4PCC 
p-value 
Composite safety 
outcome (VTE, 
stroke/TIA, cardiac 
arrest) 
58 (8.4) 5 (7.4) 18 (10.8) 0.9943 0.4013 0.5670 
    VTE/PE, n (%) 20 (2.9) 2 (2.9) 14 (8.4) 1 0.001 0.1617 
    Stroke/TIA, n (%) 13 (1.9) 0 (0) 5 (3.0) 0.6197 0.3631 0.325 
    Cardiac arrest 25 (3.6) 3 (4.4) 5 (3.0) 0.7324 0.7007 0.6941 
OR return, n (%) 37 (5.4) 23 (13.9) 14 (20.6) <0.0001 0.0002 0.2327 
Reoperation due to 
bleed, n (%) 
9 (1.3) 3 (4.4) 4 (2.4) 0.0844 0.2924 0.4175 
Renal failure, n (%) 17 (2.5) 2 (2.9) 8 (4.8) 0.6849 0.1056 0.7278 
LOS after surgery 
(days), median 
(Q1,Q3) 
8 (6,11) 11 (8,13.5) 11 (8,15) <0.0001 <0.0001 0.5412 
LOS (days), median 
(Q1,Q3) 
9 (7,13) 13 (10,18.5) 14 (9,20) <0.0001 <0.0001 <0.0001 
Death, n (%) 16 (2.3) 2 (2.9) 3 (1.8) 0.6717 1 0.6296 
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FIGURES 
Figure 1. Patient Consort Diagram 
 
Patients with CABG 
or valve procedure 
from December 
2013 to April 2016 
(n=1,946) 
Excluded (n=564)
 Unresponsive neurological state prior to procedure 
(n=6)
 Refusing blood products (n=53)
 Patient receiving other factor concentrate products 
intraop (i.e. FEIBA, factor VII, etc.) (n=25)
 Total artifical heart (n=2)
 Ventricular assist device (n=33)
 Previous aortic procedure (n=57)
 Cardiac Tumor (n=2)
 Other cardiac surgery not specified (n=2)
 Resuscitation prior to procedure (n=4)
 Robot used during procedure (n=5)
 Circulatory arrest/Cooling during procedure < 11 
degrees (n=9)
 Pulmonary valve replacement (n=7)
 Patients who did not transfer to ICU after care 
(n=2)
 Aortic Procedure Performed (n=147)
 Aortic aneurysm or dissection (n=2)
 Duplicate patients (n=3)
 Received factor product within 24 hours post-op 
(Riastap, Factor VII, or Kcentra) (n=25)
 Missing Anesthesia (n=43)
 Received kcentra within 24 hours prior to 
procedure (n=9)
 Did not receive CPB (n=180)
 Patients randomly not collected due to desired 
sample size reached (n=400)
Patients collected 
(n=982)
No 4PCC or FFP 
administered 
intraop (n=690)
4PCC administered 
intraop (n=166)
FFP administered 
intraop (n=68)
Excluded due to 
4PCC and FFP 
administered 
intraop (n=58)
Patients included in 
analysis (n=924)
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Figure 2. Propensity Score Overlap and Distribution for Sensitivity Analysis 
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APPENDIX 
 
Table 1. ICD-10 Procedure Codes for CABG 
Section 0 Medical and Surgical 
Body System 2 Heart and Great Vessels 
Operation 1 
Bypass: Altering the route of passage of the contents 
of a tubular body part 
Body Part Approach Device Qualifier 
0 Coronary Artery, One Site 
1 Coronary Artery, Two Sites 
2 Coronary Artery, Three 
Sites 
3 Coronary Artery, Four or 
More Sites 
0 Open 
9 Autologous Venous Tissue 
A Autologous Arterial Tissue 
J Synthetic Substitute 
K Nonautologous Tissue 
Substitute 
3 Coronary Artery 
8 Internal Mammary, 
Right 
9 Internal Mammary, 
Left 
C Thoracic Artery 
F Abdominal Artery 
W Aorta 
0 Coronary Artery, One Site 
1 Coronary Artery, Two Sites 
2 Coronary Artery, Three 
Sites 
3 Coronary Artery, Four or 
More Sites 
0 Open Z No Device 
3 Coronary Artery 
8 Internal Mammary, 
Right 
9 Internal Mammary, 
Left 
C Thoracic Artery 
F Abdominal Artery 
 
Table 2. Valve Repair ICD-10 Procedure Codes 
Section 0 Medical and Surgical 
Body System 2 Heart and Great Vessels 
Operation Q 
Repair: Restoring, to the extent possible, a body part 
to its normal anatomic structure and function 
Part Approach Device 
Qualifier 
 
F Aortic Valve 
G Mitral Valve 
H Pulmonary Valve 
J Tricuspid Valve  
0 Open Z No Device Z No Qualifier 
 
Table 3. Valve Replacement ICD-10 Procedure Codes 
Section 0 Medical and Surgical 
Body System 2 Heart and Great Vessels 
Operation R 
Replacement: Putting in or on biological or synthetic 
material that physically takes the place and/or 
function of all or a portion of a body part 
Part Approach Device Qualifier 
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F Aortic Valve 
G Mitral Valve 
H Pulmonary Valve 
J Tricuspid Valve  
0 Open 
7 Autologous Tissue 
Substitute 
8 Zooplastic Tissue 
J Synthetic Substitute 
K Nonautologous Tissue 
Substitute 
Z No Qualifier 
 
